

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number
WO 02/42441 A2

(51) International Patent Classification⁷: **C12N 9/64**,
15/57, C07K 16/40, C12N 5/10, G01N 33/563, A61K
38/48

(21) International Application Number: PCT/EP01/13391

(22) International Filing Date:
20 November 2001 (20.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/721,254 22 November 2000 (22.11.2000) US
09/833,328 12 April 2001 (12.04.2001) US

(71) Applicant (for all designated States except US): **BAXTER
AKTIENGESELLSCHAFT** [AT/AT]; Industriestrasse
67, A-1221 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAEMMLE,
Bernhard** [CH/CH]; Schuetzenweg 3, CH-3065 Bolli-
gen (CH). **GERRITSEN, Helena, Elisabeth** [CH/CH];
Sentenstrasse 14, CH-5623 Boswil (CH). **FURLAN,
Miha** [CH/CH]; Liebeggweg 7, CH-3006 Bern (CH).
TURECEK, Peter [AT/AT]; Hauptstrasse 59g, A-3400
Klosterneuburg (AT). **SCHWARZ, Hans-Peter** [AT/AT];
Schindlergasse 32, A-1180 Vienna (AT). **SCHEI-
FLINGER, Friedrich** [AT/AT]; Michelheurngasse 4/17,

A-1090 Vienna (AT). **ANTOINE, Gerhard** [DE/AT];
Holunderweg 11, A-2301 Gross-Enzersdorf (AT). **KER-
SCHBAUMER, Randolph** [AT/AT]; Peter Jordan Strasse
32-34/17, A-1190 Vienna (AT). **TAGLIAVACCA, Luigi-
ina** [IT/IT]; Via Ugo la Malfa, 3C, Piltello, I-20093 Milano
(IT). **ZIMMERMANN, Klaus** [DE/AT]; Harlacherweg
2/2/19, A-1220 Vienna (AT). **VOELKEL, Dirk** [DE/AT];
Podhagskygasse 2/17, A-1220 Vienna (AT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE

(57) Abstract: The invention relates to a vWF cleaving protease (vWF-cp) polypeptide, a nucleic acid molecule encoding the amino acid sequence of a vWF-cp polypeptide and a composition comprising the polypeptide. The invention also relates to the use of the vWF cleaving protease polypeptide for production of vWF cleaving protease polypeptide binding molecules and for production of a preparation for prophylaxis and therapy of thrombosis and thromboembolic disease.



WO 02/42441 A2

**von Willebrand Factor (vWF) cleaving protease polypeptide,
nucleic acid encoding the polypeptide and use of
polypeptide**

5 **Field of the Invention**

The invention relates to a vWF cleaving protease (vWF-cp) polypeptide or a partial sequence thereof, a nucleic acid molecule encoding the amino acid sequence of a vWF -cp polypeptide, and a composition comprising the polypeptide.

10 The invention also relates to the use of the vWF-cp polypeptide for production of anti-vWF-cp polypeptide antibodies and for production of a preparation for prophylaxis and therapy of thrombosis and thromboembolic disease.

15 **Background of the Invention**

vWF is a glycoprotein circulating in plasma as a series of multimers ranging in size from about 500 to 20,000 kD. Multimeric forms of vWF are composed of 250 kD polypeptide subunits linked together by disulfide bonds.

20 vWF mediates the initial platelet adhesion to the subendothelium of a damaged vessel wall, though only the largest multimers appear to exhibit haemostatic activity. Such vWF multimers having large molecular masses are stored in the Weibel Palade bodies of endothelial cells, and it is
25 believed that endothelial cells secrete these large polymeric forms of vWF. Those forms of vWF which have a low molecular weight (low molecular weight or LMW vWF) are believed to arise from proteolytic cleavage of the larger multimers.

30 A small portion of the vWF present in normal plasma circulates as 189, 176 and 140 kD fragments resulting from

proteolytic degradation of vWF *in vivo*, the 140 kD fragment being derived from the N-terminal region, and the 176 kD fragment from the C-terminal region of the subunit. When low molecular weight (LMW) forms of vWF are isolated from normal human plasma and subjected to SDS-PAGE (polyacrylamide gel electrophoreses) after disulfide reduction, an unusually high portion of vWF fragments are found. This finding is compatible with the view that LMW forms of vWF have been partially or predominantly derived from large multimers by proteolytic degradation.

The proteolytic degradation of vWF is a physiological process in healthy individuals, yet in patients suffering from von Willebrand disease (vWD) type 2A it may be accelerated, and as a consequence these patients lack the vWF multimers with the largest molecular masses. A lack of large vWF multimers and an increased level of proteolytic fragments are also observed in acquired von Willebrand disease (vWD) associated with myeloproliferation syndrome, indicating increased *in vivo* proteolysis in this condition as well.

In patients with thrombotic thrombocytopenic purpura (TTP), on the other hand, unusually large vWF multimers are detected, and increased vWF binding to platelets has been demonstrated in these patients (Moake et al. 1982, N. Engl. J. Med. 307: 1432-1435). Familial TTP is associated with a severe congenital deficiency of vWF protease, while the presence of vWF-cleaving proteases inhibiting autoantibodies has been observed in patients with non-familial TTP.

The large multimers of vWF associated with TTP normally disappear after a patient is transfused with normal fresh frozen plasma. Presently, plasma exchange is

the most important treatment for TTP, although significant side effects have been reported with this therapy. The existence of a severe congenital deficiency of vWF protease has been established in patients with familial TTP and the presence of a vWF-cleaving protease inhibiting autoantibodies has been observed in patients with non-familial TTP.

Several proteases have been shown to be able to cleave vWF, thereby impairing its binding affinity for platelets. However, *in vitro* the cleavage of vWF with these proteases in each case results in cleavage products different from the fragments derived from *in vivo* cleavage.

Thus, for example, while plasmin is capable of cleaving several peptide bonds in vWF, plasmin-treated vWF retains a high molecular weight core region retaining about 70% of its platelet agglutinating activity (determined as ristocetin cofactor). A 34 kD peptide is split from the N-termini of individual vWF subunits in the early stages of plasmin treatment, and epitope mapping of such plasmin-induced fragments show that these fragments originated from regions of the vWF subunit that are different from the vWF fragments present in circulating plasma.

Porcine pancreatic elastase and various serine proteases released from human leukocytes have also been shown to degrade vWF proteolytically with a resultant loss of large multimers. Epitope mapping of the degradation products again indicates that these fragments also differ from those present in normal plasma and in vWD type 2A. In addition, a calpain-like protease released from human platelets has been shown to degrade large vWF multimers and to create vWF fragments similar to those observed *in vivo*.

Summary of the Invention

It is an object of the invention to provide for a vWF cleaving protease (vWF-cp) polypeptide or a partial sequence thereof.

5 It is another object of the invention to provide for a composition comprising a vWF-cp polypeptide.

It is an object of the present invention to provide for a nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence of a vWF-cp polypeptide.

10

It is also an object of the invention to provide for recombinant vWF-cp polypeptide.

It is another object of the invention to provide a method of production of a recombinant vWF-cp polypeptide.

15 It is also an object of the invention to provide for a method of purification of vWF using a vWF-cp polypeptide or a partial sequence thereof.

It is also an object of the invention to provide for anti-vWF-cp polypeptide ligands.

20

Brief Description of the Drawing

Fig.1 shows the schematic purification scheme of the vWF-cp from plasma.

Fig. 2 shows the SDS-PAGE of purified of vWF-cp polypeptides under non-reducing (A) and reducing conditions in the presence of DTT (B).

25

Fig. 3 shows the partial nucleotide and amino acid sequence of the vWF-cp polypeptide.

Fig. 4 shows the schematic drawing of the genomic localization of the vWF-cleaving protease gene.

30

Fig. 5 shows the complete amino acid and nucleotide sequence of the vWF-cleaving protease. Start and end of the

signal peptide, metalloprotease, the cysteine rich region (ACR), thrombospondin type 1 motif (TSP 1), and disintegrin like motif (RGD) domains are indicated by arrows. Furin cleavage site, catalytic site and Met-turn are underlined.

5 The putative N-glycosylation sites are indicated by asteriks.

Fig. 6 shows the schematic representation of the domain organization of the vWF-cleaving protease and those of the human members of the ADAM-TS family. The domain
10 structures of the vWF-cleaving protease (ADAMTS 13) and of all known human ADAMTS proteins are shown. ADAMTS 10 cannot be found in databases and ADAMTS 11 is identical to ADAMTS 5.

Fig. 7 shows Western blot analysis of cells
15 transfected with a vector comprising vWF-cp polypeptide encoding sequences, with lane 1: standard molecular weight marker, lane 2: control vector cDNA3.1(+) and lane 3: vector pCMV-vWFcp. The specific vWF-cp polypeptide band is indicated by the arrow.

20 Fig. 8 shows SDS-Page of vWF-cp activity on vWF with lane 1: purified plasmatic vWF as control, lane 2: vWF incubated with normal human plasma, lane 3: vWF incubated with buffer as control, lane 4: vWF incubated with of cell lysate of SK-Hep cells transfected with control vector
25 cDNA3.1(+) and lane 5: vWF incubated with of cell lysate of SK Hep cells transfected with vWF-cp expressing vector pCMV-vWFcp.

Detailed Description of the Invention

30 In accordance with one of the objects of the invention there is provided a vWF-cp polypeptide comprising (a) an amino acid sequence selected from the group of SEQ ID. NO.

1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of (a). Polypeptide molecules can also have at least 90%, or at least 95% identity to the amino acid sequence of (a). The polypeptide preferably has an amino acid sequence as shown in Fig. 5 or a partial sequence thereof of at least 12, preferably at least 15 amino acids. Preferably, the vWF-cp polypeptide has vWF cleaving activity. The vWF-cp polypeptide of the invention preferably retains vWF protease activity in the presence of serine protease inhibitor and a calpain protease inhibitor. The serine protease inhibitor can be diisopropyl fluorophosphate or any analogue thereof which has serine protease inhibitor activity. The calpain inhibitor can be Z-Leu-Leu-Tyr-CHN2 or any analogue thereof having calpain inhibitor activity.

The term "polypeptide" means a chain of amino acid residues linked through peptide bonds between the α -carboxyl carbon of one amino acid residue and the α -nitrogen of the next amino acid, and comprising 10 or more amino acid residues joint together. The polypeptide may contain other than the 20 gene-encoded amino acids. "Polypeptide" refers both to short chains, such as peptides, oligopeptides, or oligomers, and to longer chains, generally referred to as proteins. "Polypeptide" include amino acid sequences modified either by natural processes, such as posttranslational modifications, or chemical modifications, which are known in the art. Modifications can occur anywhere in the polypeptide. The modification may lead to a variant of the polypeptide which

may differ in amino acid sequence from original polypeptide by one or more substitutions, additions, deletions, fusions or any combination, or a naturally occurring variant, such as an allelic variant or non-naturally occurring variant

made by mutagenesis or genetic engineering. The

"Polypeptide" may be in form of an unprocessed or partial processed precursor, the "mature" polypeptide, or a fragment having an amino acid sequence that entirely is the same as a part, but not all, of the amino acid sequence of

the longer a polypeptide chain. Fragment may be a shorter single continuous region of the longer chain, or comprised within a larger polypeptide of which they form a part. A Fragment of polypeptide may include, for example a truncated polypeptide having a partial amino acid sequence

of the vWF-cp. A "Fragment" can be a biological active fragment that mediate vWF cleaving protease activity, including those with similar activity or improved activity, or with decreased activity.

"Identity" means the identity of the amino acid sequence of a polypeptide to the amino acid sequence of a polypeptide comprising the sequence of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5. "At least 80% identity", means that the amino acid sequence is identical except that the polypeptide sequence differs in not less than 20 amino acids per 100 amino acids. "At least 90%" or "at least 95% identity" means a difference of not less than 10, or not less than 5 amino acids per 100 amino acids.

The term "vWF cleaving protease" (vWF-cp) means a protein or polypeptide having vWF cleaving activity and cleaves vWF high molecular vWF multimers in molecules of

lower molecular weight which still have vWF activity and properties.

The term "vWF cleaving protease polypeptide" means a polypeptide having at least 10 amino acid residues. The complete amino acid sequence of the unprocessed polypeptide comprises 1427 amino acids. The "mature" polypeptide, which is a part of the larger unprocessed polypeptide should normally begin with or near amino acid 75, beginning with AAGGILH, and continuing to the carboxyl terminus. The mature vWF cleaving protease has a calculated polypeptide mass of about 145 KD. Additional amino acids which contains secretory or leader sequences, pro-sequences, sequences which aid purification or identification such as multiple His residues, a FLAG tag or and additional sequence for stability during recombinant production, can be included.

The term "vWF cleaving activity" means a physiological vWF cleaving activity which is defined by (1) the cleaving vWF at the peptide bond 842Tyr-843Met, (2) having a direct proteolytic activity which converts vWF having a singlet structure to vWF having a satellite structure, and (3) retaining activity in the presence of a serine protease inhibitor such as diisopropyl fluorophosphate (DFP) and in the presence of a calpain protease inhibitor such as carbobenzyloxy (Z) peptidyl diazomethylketone inhibitor (Z-Leu-Leu-Tyr-CHN₂). The proteolytic entities provided with the present invention may also act indirectly via another effector protein, for example a protease. This polypeptide can form an active vWF cleaving complex together with a metal ion selected from the group consisting Ca⁺⁺, Sr⁺⁺, Mg⁺⁺ and Ba⁺⁺. The preferred metal ion is Ca⁺⁺. This active complex is able to cleave vWF in a physiological manner as

described above. The vWF cleaving activity of the polypeptide according to the present invention may be determined by any method described in the art, such as the method according to Furlan et al. (1996, Blood 87: 4223-4234) or as described in WO 00/50904. Alternatively, a collagen binding assay, e.g. as described in EP 0 816 852, can also be used as a test system.

According to one aspect, the invention provides for an isolated polypeptide comprising an amino acid sequence having at least 80% identity to the amino acid sequence selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. According to one embodiment of this aspect of the invention the isolated polypeptide comprises an amino acid sequence selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5.

The term "isolated" means altered from the natural state and/or removed from its original environment.

The invention also provides for a substantially pure vWF-cp polypeptide comprising (a) an amino acid sequence of selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of (a).

The term "substantially pure" means purity as high as the relative proportions of polypeptide chains with the vWF-cp activity present in an amount of above 50%, especially above 80%, most preferred about 90%, of total protein compared to the vWF protease activity in plasma. The purity is determined by a purity as determined by SDS-

PAGE (silver stained or Commassie stained) and Western blot and a ratio of vWF protease polypeptide to total protein amount, said purity is preferably greater than about 98%. If the purified vWF-cp polypeptide is purified from plasma the preparation contains between 0.001% and 1%, preferably 0.002% of the initial amount of plasma protein, and at least 1%, preferably at least 2.3% of the initial enzyme activity, which may be partially inactivated during the purification procedure. The preparation comprising a vWF - cp polypeptide according to the present invention is essentially free of vWF or vWF fragments, i.e. having a vWF content of below 5%, preferably below the detection limit of an assay used to detect vWF, such as a collagen-assay described in EP 0 816 852.

The substantially pure vWF-cp polypeptide exhibits an apparent molecular weight of about 180 KD, 170 kD, 160 kD or 120 KD in SDS-PAGE analysis under reducing conditions.

The substantially pure vWF protease polypeptide exhibits an apparent molecular weight of about 150 KD, 140 kD, 130 kD or 110 KD in SDS-PAGE analysis under non-reducing conditions.

The SDS-PAGE is performed under reducing conditions or non-reducing conditions. It is well known in the art, that molecular weight determination using SDS PAGE results in the detection of apparent molecular masses, which may be different from the molecular masses of the native, non-denatured protein.

Analysis of non-denatured material by mass spectrometry showed very broad peaks of high molecular weight. This finding is in agreement with appearance, in gel filtration experiments, suggesting that the proteins in this preparation tend to polymerize under physiologic

conditions (a property of clusterin).

The polypeptide of the invention can be isolated from any source which comprising a vWF-cp polypeptide.

5 The term "source" means human plasma, a supernatant of a cell culture expressing a vWF -cp polypeptide according to the present invention, milk or other body fluids of transgenic animals expressing the polypeptide of the invention.

10 Purification of vWF-cp polypeptide can be performed by a combination of chromatographic steps including immunoaffinity chromatography, gel filtration, and ion exchange chromatography. For example, the first purification step can be immunoaffinity chromatography, the
15 second step can be gel filtration, followed by one or more additional immunoaffinity chromatography steps. A further purification can be performed using ion exchange chromatography, preferably anion exchange chromatography and at least one affinity chromatography. Further
20 purification steps can be performed using ion exchange chromatography, gel filtration and further affinity chromatography steps.

25 According to one aspect of the invention there is provided a composition comprising a vWF-cp polypeptide comprising (a) an amino acid sequence selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of
30 (a).

The composition of the invention comprising the polypeptide may further comprise a divalent metal ion

selected from the group of Ca^{2+} , Sr^{2+} , Ba^{2+} and Mg^{2+} .

A further aspect of the present invention relates to a complex of isolated vWF-cp polypeptide having vWF-cp activity, vWF and a metal ion selected from the group consisting of Ca^{2+} , Sr^{2+} , Ba^{2+} and Mg^{2+} . The preparation may comprise divalent metal ions in a concentration of about 1 to 10^6 ions per polypeptide molecule with vWF protease activity and can contain vWF -cp polypeptide in an essentially purified form.

The composition may comprise clusterin or an analog or derivative thereof having clusterin activity. With relation to the activity of the protein, the term "derivative" or "analog" of clusterin refers to a polypeptide that show the same characteristics as the native clusterin protein.

Clusterin is a heterodimeric glycoprotein consisting of two non-identical subunits, with a molecular mass of approximately 80 kDa (Rosenberg et al. 1995, Int. J. Biochem. Cell Biol. 27: 633-645; Tschopp et al. 1994, Clin. Exp. Immunol. 97(Suppl. 2): 11-14). It is produced in a wide array of tissues and found in most biologic fluids. The physiologic functions described in the prior art include complement regulation, lipid transport, sperm maturation, initiation of apoptosis, endocrine secretion, membrane protection and promotion of cell interactions. It has been found that the unusually high stability of the vWF -cp polypeptide of the present invention in circulating plasma is associated with the presence of clusterin and that the half-life of vWF cleaving protease activity *in vivo* is between 1 and 4 days, while other proteases in plasma have half-lives in the range of seconds to hours. The ratio of clusterin to vWF protease polypeptide in a

composition according to the present invention is preferably in a range of 10M:1M to 1M:10M, and more preferably the ratio of clusterin and vWF is in the equimolar range. In human plasma, the concentration of vWF-cleaving protease is 2 - 10 mg/liter whereas that of clusterin is 50 - 400 mg/liter plasma (the molar ratio of vWF-cleaving protease to clusterin in human plasma is about 1:20 - 1:100).

In accordance with one of the objects of the invention there is provided a nucleic acid molecule comprising a nucleic acid sequence encoding vWF-cp polypeptide having (a) an amino acid sequence selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of (a).

The term "nucleic acid molecule" means a polynucleotide and generally refers to any DNA or RNA, which also includes variants of the DNA or RNA, the DNA or RNA which may be modified or unmodified, single- and double stranded or a mixture thereof, or a short polynucleotide, generally referred to as oligonucleotides. A typical variant of a polynucleotide differs in nucleotide sequence from the original polynucleotide in sequence and may or may not alter the amino acid sequence of the polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions or truncations in the polypeptide sequence of the polypeptide. The polynucleotide sequence may be modified to improve recombinant expression. Such modification includes use of highly translated codons. Nucleic acid sequence which do hybridize with the DNA

sequence as shown in Fig. 5 or partial sequence encoding an amino acid of at least 12 amino acid are within the scope of the present invention. Hybridization Techniques are well known to the skilled artisan.

5

According to another aspect of the invention there is provided an expression vector comprising a nucleic acid molecule comprising a nucleic acid sequence encoding a vWF-cp polypeptide having (a) an amino acid sequence of
10 selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of (a).

The nucleic acid molecule of the invention can be
15 used for constructing expression systems providing appropriate elements for replication of vector within a host cells and expression of the DNA which can then be used for the expression of a polypeptide having vWF cleaving protease activity according to the present invention. The
20 nucleic acid sequence may be modified to improve expression, such as addition of a Kozak sequence.

The expression vector may comprise, for example, in the direction of transcription, a transcriptional regulatory region and a translational initiation region
25 functional in a host cell, a DNA sequence comprising a polynucleotide expressing a VWF -cp polypeptide according to the present invention and translational and transcriptional termination regions functional in said host cell, wherein expression of the nucleic sequence is
30 regulated by the initiation and termination regions. The expression vector may also contain elements for the replication of the nucleotide. Examples of DNA expression

vectors are pBPV, pSVL, pRc/CMV, pRc/RSV, myogenic vector systems, pcDNA3 based vector (Invitrogen) or vectors derived from viral systems, for example from vaccinia virus, adenoviruses, adeno-associated virus, herpes viruses, retroviruses or baculo viruses. Suitable mammalian expression vectors usually contain one or more eukaryotic transcription units that are capable of expression in mammalian cells. The transcription unit is comprised of at least a promoter element to mediate transcription of foreign DNA sequences. Suitable promoters for mammalian cells are known in the art and include viral promoters such as that from simian virus 40 (SV40), cytomegalovirus (CMV), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV) or other promoters selected from the group of methallothionein promoter and β -Actin promoter. Other promoters known in the art are also applicable for expression.

The expression vector containing the nucleic acid sequence which encodes the vWF-cp polypeptide according to the present invention can be used to transform host cells which then produce the polypeptide. The transformed host cells can be grown in a cell culture system to produce the polypeptide *in vitro*. The host cells can excrete the polypeptide having vWF protease activity into the cell culture medium from which it can be prepared or the polypeptide can be isolated from the cell lysate.

The expression vector comprising the nucleic acid molecule encoding a polypeptide comprising (a) an amino acid sequence of selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity

to the amino acid sequence of (a) can be transformed or transfected into a host cells for expression of the recombinant polypeptide. Suitable host cells include any cell capable of producing vWF -cp polypeptide after being transformed or transfected. Preferred cells include bacterial cells, yeast, insect cells or animal cells. The host cell may be a cell derived from the body of a mammal, for example fibroblasts, keratinocytes, hematopoietic cells, hepatocytes or myoblasts, which are transformed *in vitro* with an expression vector system carrying a nucleic acid according to the present invention and re-implanted into the mammal. The polypeptide according to the present invention encoded by said nucleic acid will be synthesized by these cells *in vivo* and they will exhibit a desired biological activity in the mammal.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). Exemplary mammalian host cells include particularly primate cell lines and rodent cell lines, including transformed cell lines. Preferably for stable integration of the vector DNA, and for subsequent amplification of the integrated vector DNA, both by conventional methods, Chinese hamster ovary (CHO) cells are employed as a mammalian host cell of choice. Other suitable cell lines include, but are not limited to, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS-1), human hepatocellular carcinoma cells (e.g., Hep G2), human adenovirus transformed 293 cells, HEK 293cells, SKHep cells, mouse L-929 cells, HaK hamster cell lines, murine 3T3 cells derived from Swiss, Balb-c or NIH mice and a number of other cell lines. Another suitable mammalian cell

line is the CV-1 cell line. Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants, are also suitable. Candidate cells may be genotypically deficient in the selection gene,
5 or may contain a dominantly acting selection gene.

Host cells can be either transformed cells or untransformed cells. The host cells are preferably those expressing furin either naturally or after being genetically engineered to express recombinant furin.

10 The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art.

15 The host cell transformed with a vector carrying the vWF-cp polypeptide encoding nucleic acid may then be cultured under suitable conditions if desired, with amplification introduced genes. Effective conditions include, but are not limited to, appropriate media,
20 bioreactor, temperature, pH and oxygen conditions that permit protein production. The method of this present invention therefore comprises culturing a suitable cell or cell line, which has been transformed with a nucleic acid sequence encoding a amino acid sequence of the vWF-cp
25 polypeptide, the coding sequence under the control of a transcriptional regulatory sequence. The expressed polypeptide is then recovered, isolated and purified from the culture medium if secreted by the cells or from the cell, if expressed intracellularly by appropriate means
30 known to one of skill in the art.

The nucleic acid molecule of the invention or a fragment thereof can be expressed in a eukaryotic or

prokaryotic microorganism system, such as fungi, including yeast, or bacteria. Fragments can include truncated forms of the vWF cleaving protease. Examples of truncation include, but are not limited to, N-or C-terminal deletions.

5

The nucleic acid molecule of invention may also be used to generate transgenic animals, which express said polypeptide *in vivo*. In one embodiment of this specific application, the transgenic animals may express the vWF -cp polypeptide in endogenous glands, for example in mammary glands from which the said proteins are secreted. In the case of the mammary glands, said vWF protease polypeptide is secreted into the milk of the animals from which said proteins can be prepared. The animals may be mice, cattle, pigs, goats, sheep, rabbits or any other economically useful animal.

10

15

The vWF-cp polypeptide of the invention can be used in a method of purification of vWF by providing as a ligand for vWF a vWF-cp polypeptide of the invention, contacting a solution comprising vWF with the vWF-cp polypeptide ligand under conditions whereby vWF is bound to the ligand and recover from said ligand purified vWF. The vWF-cp polypeptide ligand may be bound to a solid carrier.

20

25

Furthermore, the vWF-cp polypeptide of the invention can also be used for the development of vWF-cp polypeptide binding molecules using techniques known in the art. The binding molecules can be anti-vWF-cp polypeptide antibodies which can be produced by immunization of an animal with a polypeptide of the invention and isolation of anti-vWF-cp polypeptide antibodies from the animal.

30

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric antibodies, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library, peptides or peptidomimetics. Monoclonal antibodies can be produced according to methods well known in the art. Other binding molecules can be derivatives of a antibody, such as a single chain antibody, a Fab-, or Fab'2-fragment, a chimeric antibody, or a peptide or a peptidomimetic, which can be obtained by known methods such as e.g. the phage display method.

Within the aspect of the invention, a vWF-cp polypeptide binding molecule selected from the group of single chain antibodies, Fab- or Fab'2-fragment or polypeptides with vWF protease binding site can be produced by a method, wherein a phage display library is screened for anti-vWF-cp polypeptide binding molecule, the nucleic acid sequence of positive clones is determined and a nucleic acid molecule comprising the sequence is cloned into an expression vector.

The development of the antibodies, antibody derivatives, peptidomimetics or any other molecule which binds vWF-cp polypeptide can be accomplished according methods known to the prior art (Greer et al. 1994, J. Med. Chem. 37: 1035-1054; Kemp 1990, Trends Biotechnol. 8: 249-255).

The vWF-cp polypeptide binding molecule of the invention may be used as a ligand to purify vWF-cp. Such a method can be performed by contacting a solution comprising vWF-cp polypeptide with the vWF-cp polypeptide binding molecule under conditions whereby vWF-cp polypeptide is bound to the binding molecule and recovering purified vWF-

cp polypeptide by selectively eluting vWF-cp polypeptide from the vWF-cp binding molecule. The vWF-cp binding molecule may be bound to a solid carrier.

5 The vWF-cp polypeptide binding molecule can be also be used in a method for detection of vWF-cp polypeptide in a sample. Thereby a solution suspected to contain vWF-cp polypeptide is contacted with a vWF-cp polypeptide binding molecule as described above under conditions allowing the
10 formation of a complex of vWF-cp polypeptide/vWF-cp polypeptide binding molecule and detection of the complex.

 The vWF-cp polypeptide of the invention can be used, for example, to process plasmatic or recombinantly produced
15 vWF. Recombinant vWF (r-vWF) can be produced in CHO cells, e.g. according to Fischer et al. (1995. FEBS Lett 375: 259-262). The r-vWF recovered in this manner is available as a mature vWF and has a singlet structure, i.e. it differs from plasma-derived vWF, which always has a characteristic
20 satellite structure when examined on 2% SDS agarose gels. US5,854,403 teaches that r-vWF is comprised of multimers with high structural integrity which is retained even after purification and treatment for the inactivation of viruses. The intact structure of the r-vWF is defined by a result of
25 electrophoretic analysis consisting of multimer bands with an absence of satellite bands. To prepare an r-vWF preparation having a structure more closely corresponding to that of plasma-derived vWF from r-vWF with singlet structure, r-vWF is treated with the vWF protease
30 polypeptide or a composition comprising the vWF-protease polypeptide of the present invention, and optionally metal ions and/or clusterin.

According to one aspect of the invention, the vWF-cp polypeptide can be used for the production of a preparation for the prophylaxis and therapy of diseases that show supranormal vWF content or an increased level of high-molecular weight vWF in patients, such a thromboembolic disease. This can result in thromboses and thromboembolic diseases. For example, thrombotic thrombocytic purpura (TTP), Henoch-Schönlein purpura, preeclampsia, neonatal thrombocytopenia or haemolytic-uremic syndrome. By administering an effective dose of a polypeptide of the invention and having a vWF protease activity, this can lead to reduction of the content of high molecular weight vWF multimers in the patients, resulting in effective therapy of these diseases. The disease can be selected from the thromboembolic disease is thrombotic thrombocytic purpura (TTP), Henoch-Schönlein purpura, preeclampsia, neonatal thrombocytopenia or hemolyticuremic syndrome.

The invention is described in the following examples, without being limited thereto.

Examples

Example 1:

Isolation of vWF-cp polypeptides

5 1.1. Preparation of an IgG-eTTP-coupled affinity gel. The IgG-eTTP is isolated by aid of a 20 ml protein A-Sepharose® (diameter 1.6 cm) in TBS, pH 7.4. Pheresis plasma of a patient suffering from acquired TTP ("erworbenes" TTP; eTTP), which previously had been assayed
10 for its inhibitor content relative to the vWF-cleaving protease is applied to the column in a volume of 50 ml. After subsequent rinsing with TBS, pH 7.4, the bound IgGs are step-wise eluted with citrate, 0.1 M, pH 4.0, and glycine, 0.1 M, pH 2.7. The fractions immediately are
15 brought to a physiological pH by adding Tris, 1.5 M, pH 8.8, and dialysed against TBS, pH 7.4. The Affi-Gel® Hz is coupled according to the producer's instructions with the IgG-eTTP which had been ished out of the protein A-Sepharose® with a pH of 4.0. The column material prepared
20 in this manner first is ished as prescribed, subsequently it is washed 3 times alternately with 50 ml of buffer B and 200 ml of buffer A (chapter 1.7). Prior to use, intensive rinsing with buffer A is carried out in each instance.

25

1.2 First Step

As the starting material, 100 ml of pooled CPD plasma which had come from at least three donors and had been stored at -20°C, is used after centrifuging at 2,500 rpm
30 (1,100g) for 5 min. At a relatively low flow rate (FR: 30 ml/h), the plasma is loaded on a 200 ml chromatographic

column with IgG-eTTP Affi-Gel® Hz (hydrazide, diameter 2.6 cm) which had been equilibrated in buffer A. After washing with at least 400 ml of buffer A over night at the same flow rate, a 200 ml desalting gel filtration column (Bio-Gel® P-6DG, diameter 2.6 cm) and a 10 ml protein G-Sepharose® (diameter 1.6 cm), which previously also had been rinsed with buffer A, is connected thereto. After the flow rate had been increased to 100 ml/h, the proteins bound to Affi-Gel Hz are eluted directly with 50 ml of buffer B onto the Bio-Gel® P-6DG so as to remove from the proteins the NaSCN that had been in buffer B. The proteins which had been eluted from the desalting column prior to the NaSCN are led through the protein G Sepharose® without interruption, where they are freed from the IgGs. Here, the flow rate is loared to 50 ml/h so as to extend the dwell time of the proteins in the 10 ml column. For regeneration, the protein G-Sepharose® is shortly washed with buffer C, and the eluted IgG fraction is stored for analysis.

The first step is carried out 8 times before the collected fractions which had been frozen at -20°C are pooled and further processed.

1.3 Second Step

The pooled fractions from 8 chromatographies of the first step are diluted 1:1 with H₂O so as to obtain an ionic strength at which the desired proteins would bind to the anion exchange column (High Q Support®). The sample whose volume is from 1,500 to 1,800 ml, depending on the charge used, is checked for its pH and its ionic strength and applied over night at a FR of 90 ml/h through a 50 ml

column with Therasorb® (diameter 1.6 cm) onto a 5 ml High Q Support® (diameter 1.6 cm). Both, Therasorb and High Q Support® had previously been equilibrated in buffer D. After washing with approximately 150 ml of buffer D, the
5 Therasorb is disconnected, and the 25 ml Lentil Lectin Sepharose® (diameter 1.6 cm) which had been equilibrated in buffer E is connected to follow the High Q Support®. At a FR of 60 ml/h, the proteins bound to High Q Support are immediately eluted with buffer E directly to the Lentil
10 Lectin-Sepharose®. The proteins which bound to the Lentil Lectin-Sepharose® can be eluted in two steps with buffers G and H and can be collected. The proteins which had remained bound to Therasorb and High Q Support® are washed out with buffer C or buffer F, respectively, and discarded
15 after an analysis.

For regeneration, before being used, the Lentil Lectin-Sepharose® in each case is rinsed according to the producer's instruction 3 times alternately with 20 ml each of buffers I and J, the High Q Support is rinsed
20 successively with 10 ml each of NaOH 1N and NaCl 1M.

1.4 Third Step

The pooled fractions which had been eluted from the Lentil Lectin-Sepharose® with buffer H are dialysed three
25 times for a total of 4 h, each against 1 l of buffer D, and again applied to the High Q Support at a flow rate of 60 ml/h. Connected thereinafter is a 5 ml heparin-Sepharose (diameter 1.4 cm), which likewise had been equilibrated in buffer D. After the application of the sample, it is rinsed
30 with approximately 50 ml of buffer D, the heparin-Sepharose

is disconnected, and a 500 ml Sephacryl® S-300 HR (diameter 2.6 cm), which had been equilibrated in buffer L, is connected thereto. The proteins bound to High Q Support are directly eluted to the gel filtration column with 10 ml of buffer K. The exclusion chromatography is effected at a flow rate of 42 ml/h, and the fractions are collected at 7 ml each. The proteins which are more strongly bound to High Q Support® are again eluted with buffer F, those which remained adhered to the heparin-Sepharose, with buffer K.

1.5 Fourth Step

The pool of the active fractions from the third step is applied without treatment at a FR of 10 ml/h to a 1 ml anti- α_2 -macroglobulin column (flow rate 0.7 ml/min) which had been equilibrated in buffer L. The anti- α_2 -macroglobulin column is prepared by immobilization according to the instructions, of rabbit-anti- α_2 -macroglobulin antibodies at a concentration of 4.9 mg/ml on CNBr-activated Sepharose. The proteins bound thereon are eluted with NaSCN 3M in buffer L and with buffer C and stored for analysis.

Table 1: List of buffers

buffer A	Tris NaCl Na ₃ -citrate Na acid	10 mM 0.15 M 1mM 0.02%	pH 7.4
buffer B	NaSCN in buffer A	3.0M	pH 7.4
buffer C	glycine Na acid	0.1M 0.02%	pH 2.7
buffer D	Tris NaCl	10mM 75mM	pH 7.4
buffer E	Tris NaCl MnCl ₂	20mM 0.5M 1 mM	pH 7.4
buffer F	Tris NaCl	10mM 1.0M	pH 7.4
buffer G	Tris NaCl Methyl- α -D- mannopyranoside	20mM 0.5M 30mM	pH 7.4
buffer H	Tris NaCl Methyl- α -D- mannopyranoside	20mM 0.5M 0.3M	pH 7.4
buffer I	Tris NaCl	20mM 0.5M	pH 8.5
buffer J	Na acetate NaCl	20mM 0.5M	pH 5.5
buffer K	Tris NaCl	10mM 0.5M	pH 7.4
buffer L (TBS)	Tris NaCl	10mM 0.15M	pH 7.4

Table 2: List of Chromatographic materials

Material	Provider /Company
affi-gel hydrazide gel®: for immobilizing specific IgG's	Bio-Rad, Hercules, CA, USA
anti- α_2 -macroglobulin column: isolation of α_2 -macroglobulin	applicant's own production (see 1.5): rabbit-anti-human- α_2 -macroglobulin antibody on CNBr activated Sepharose 4B; 4.9 mg/ml
Bio-Gel® P6-DG, medium: gel filtration with exclusion limit > 6kDa	Bio-Rad
CNBr activated Sepharose 4B®: for immobilizing proteins	Amersham Pharmacia Biotech, Uppsala, S
heparin Sepharose, HITrap® 5ml: affinity chromatography: binds various proteins	Amersham Pharmacia
High Q Support®, Macro-Prep: strong anion exchanger	Bio-Rad
IgG-eTTP Affi-gel Hz: for binding vWF-protease	applicant's own production (see 1.1.): IgG-eTTP on Affi-gel Hz hydrazide
Lentil Lectin-Sepharose 4B: affinity chromatography: binds to sugar residues of proteins	Amersham Pharmacia
protein A Sepharose® CL-4B. binds IgG of type 1, 2 and 4	Amersham Pharmacia
protein G Sepharose® 4FF: isolation of IgGs of all types	Amersham Pharmacia
Sephacryl® S-300 HR: gel filtration for MWs 10,000 to 1,500,000	Amersham Pharmacia
Therasorb: coupled with sheep-anti-human-Ig-antibodies: isolation of human immunoglobulins	Serag-Wiessner, Naila, D

1.6 Fifth Step

Alternatively, or in addition to step four, an anti-clusterin column chromatography as a further step can be applied. The samples are prepared identically to the anti-
5 $\alpha 2$ - macrogluobulin-column using anti-clusterin antibodies.

1.7. SDS-Page reduced/non-reduced

The final preparation from the third step of isolation is electrophoresed on a 1.5 mm-thick SDS-polyacrylamide gel according to Laemmli (1970, Nature, 227: 680-685). A
10 gradient of 4 to 12% polyacrylamide is used for fractionation of proteins. After electrophoresis under non-reducing or reducing conditions (final concentration 65 mmol/l dithiotreitol DTT), the proteins are made visible
15 by silver stain or Commassie blue stain (Fig. 2). Under non-reducing conditions bands having a molecular weight (MW) of about 150 kD, 140 kD, 130 kD and 110 kD are detectable and under reducing conditions of about 180 kD, 170 kD, 160 kD and 120 kD.

1.8 Determination of vWF protease activity

The different fractions isolated by the purification process as described above are tested for vWF cleaving activity by the method as described by Furlan et al.
25 (1996. Blood 87: 4223-4234).

Example 2:**Amino acid sequencing and amino acid analysis of the vWF-cp polypeptide**

5 The final protein preparation from the third step of isolation is electrophoresed on a 1.5 mm-thick SDS-polyacrylamide gel according to Laemmli (1970, Nature, 227: 680-685). A gradient of 4 to 12% polyacrylamide is used for fractionation of high molecular weight proteins, and a
10 gradient of 8 to 12% polyacrylamide for low molecular weight proteins. After electrophoresis under non-reducing or reducing conditions (final concentration 65 mmol/l dithiotreitol), the proteins are blotted onto PVDF-membranes and stained for 2 min with 0.25% Coomassie Blue
15 in 45% methanol, 9% acetic acid and 46% H₂O. After rinsing with a mixture of 50% methanol, 10% acetic acid and 40% H₂O, the visible protein bands are cut out and analyzed on a Procise-cLC Sequencer (Foster City, CA) at the Chemical Institute of the University of Bern.
20 The N-terminal amino acid sequence of polypeptide bands separated by SDS-PAGE of purified vWF-cleaving protease is shown in Table 3.

Table 3: Determination of N-terminal amino acid sequence of vWF-cp

Molecular weight	Amino Acid sequence
350 kDa unreduced	Ser-Val-Ser-Gly-Lys-Pro-Gln-Tyr-Met-Val*
150 kDa unred.	Ala-Ala-Gly-Gly-Ile
140 kDa unred.	Ala-Ala-Gly-Gly-Ile
130 kDa unred.	Ala-Ala-Gly-Gly-Ile
110 kDa unred.	Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu
70 kDa unred.	Asp/Ser-Gln/Leu-Thr/Met-Val/Pro-Ser/Phe**
180 kDa reduced	Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu
170 kDa reduced	Ala-Ala-Gly-Gly-Ile
160 kDa reduced	Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val-Gly
120 kDa reduced	Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val-Gly
40 kDa reduced	Asp-Gln-Thr-Val-Ser**

* identified as α 2-macroglobulin

** identified as clusterin

Analysis of the composition of the amino acids is performed from the same sample as used for amino acid sequencing. The protein bands are hydrolyzed in the gas phase over 6 N HCl for 22 hours at 110°C and the amino acids are determined by high-performance liquid chromatography. Four unreduced polypeptide bands from SDS-PAGE of purified vWF-cp with M_r 150, 140, 130, and 110 kDa are analyzed. The results are shown in Tab. 4.

Table 4: Amino acid composition of isolated vWF-cp polypeptide

Amino acid	No. residues/100 residues			
	150 kDa	140 kDa	130 kDa	110 kDa
Asx	6.7	7.0	7.4	8.3
Glx	12.2	12.0	12.8	11.8
Ser	8.4	8.9	8.8	9.2
Gly	11.8	12.1	12.1	12.9
His	2.5	2.3	2.5	2.4
Arg	8.3	7.6	8.1	7.2
Thr	5.6	5.5	5.6	5.7
Ala	10.1	9.5	9.6	8.2
Pro	8.9	8.5	8.3	8.1
Tyr	2.1	2.7	2.3	2.4
Val	7.0	6.9	6.7	6.5
Ile	2.7	2.9	2.6	3.0
Leu	10.0	9.9	9.1	9.7
Phe	2.6	2.8	2.6	3.2
Lys	1.0	1.3	1.3	1.4

5

10

Example 3:**Identification of the vWF-cp gene**

The nucleic acid coding sequence of the amino acid sequence of peptide AAGGILHLELLVAVG (SEQ. ID. NO. 2) of the N-terminal 15 residues of the purified plasmatic human vWF-cp is determined and corresponds to the nucleic acid sequence GCT GCA GGC GGC ATC CTA CAC CTG GAG CTG CTG GTG GCC GTG GGC (SEQ. ID. No. 9). A database searching in the NCBI GenBank (<http://www.ncbi.nlm.nih.gov/>) showed the location of the corresponding nucleic acid sequence GCT GCA GGC GGC ATC CTA CAC CTG GAG CTG CTG GTG GCC GTG GGC (SEQ.ID.No. 9) on chromosome 9 clone RP11-244N20 (AL158826, GI11544459). Thus the nucleotide sequence from base 150001 to 185911 is screened for potential exons. Consecutive overlapping genome-segments with various lengths (1500 bases-5000 bases) are analysed using search engines that are queried via the internet-explorer. The genomic sequence segments, its translations and the results of the search are managed using the 'Vectors NTI Suite1 v.5.2' computer-program (Informax Inc., USA). The sequence of RP11-244N20 has a size of approximately 185 kb and the identified nucleic acid sequence starts at position 156.653. Use of an exon search program (Grail, <http://compbio.ornl.gov/Grail-1.3>) allowed identification of about 30 putative exons upstream and downstream of position 156.653. The first four exons of the search are translated into the corresponding amino acid sequence and these sequences are searched for homologies. This search revealed that each sequence displays high homology with the amino acid sequence of the family of human disintegrin and metalloproteinases with thrombospondin motifs (ADAM-TS). In order to connect the putative exons poly-A -RNA from

liver is reverse transcribed and the cDNA is then PCR amplified with primers specific for some of the putative exons (Table 5). The PCR products of primers 6142 (SEQ.ID.No.16)-6277 (SEQ.ID.No.17), 6142 (SEQ.ID.No.16)-6546 (SEQ.ID.No.18), 6351 (SEQ.ID.No. 19)-6546 (SEQ.ID.No. 18), 6278 (SEQ.ID.No. 21)-6407 (SEQ.ID.No. 20), 6346 (SEQ.ID.No. 23)-6395 (SEQ.ID.No. 24) and 6406 (SEQ.ID.No. 25)-6506 (SEQ.ID.No. 26) (derived from putative exons 1-6, 3-11, 6-11, 10-14, 13-16, 14-23, respectively) revealed bands of the expected size. After sequencing an open reading frame from exon 1 to exon 23 located near to the 3' end of clone RP11-244N20 can be identified. The 3' end of the cDNA sequence is examined by PCR amplification of the cDNA using forward primer 6548 (SEQ.ID.No. 27) of exon 22 and the specific MC18 sequence of the RT primer spdT. The resulting fragment of a size approximately to 1.8 kb is sequenced and after database search the 3' part of the new cDNA sequence can be located on region q34 (AC002325) on chromosome 9.

The unknown sequence of the gene at the 5' end is identified by 5' -RACE and sequencing of the resulting PCR product revealed two additional exons. None of the next five exons upstream of exon 1-2 can be connected by PCR to the already known cDNA sequence. All together 29 exons with a cDNA size of 4.6 kb are found. The vWF -cleaving protease gene spans approximately 37 kb, a schematic drawing of the localization of the exons is shown in Figure 4. The complete cDNA sequence is depicted in Figure 5.

Table 5 Sequences of Primers Used for Reverse Transcription, PCR and Cloning

spdT	5'-GAGCAAAATTCCTGTACTGAC (T) ₃₀ NN-3' (SEQ.ID.No. 12)	production of cDNA
MC18	5'-GAGCAAAATTCCTGTACTGAC-3' (SEQ.ID.No. 13)	specific part of spdT
5 6434	5'-GACCACGCGTATCGACGTCGAC-3' (SEQ.ID.No. 14)	anchor Primer
6275	5'-CTCAGGGTTGATGGTCTGGCT-3' (SEQ.ID.No. 15)	exon 5 reversed
6142	5'-CGGGCTGCAGGGGGGATCCTACACCTGGAG-3' (SEQ.ID.No. 16)	exon 3 forward
6277	5'-AATGTTGACTCCAGGTCGAG-3' (SEQ.ID.No. 17)	exon 6 reversed
6546	5'-TGGAGGTCAGCACCAACACA-3' (SEQ.ID.No. 18)	exon 11 reversed
10 6351	5'-GAGTTGCCCTGATGGTAACCG-3' (SEQ.ID.No. 19)	exon 6forward
6407	5'-GAGCCCTTCCGTGGGCTGCA-3' (SEQ.ID.No. 20)	exon 14 reversed
6278	5'-CGCTCCCTGGTGGAGCTGACC-3' (SEQ.ID.No. 21)	exon 10 forward
6561	5'-CTCACCATCGTCTCTCCCAT-3' (SEQ.ID.No. 22)	exon 23 reversed
6346	5'-ATCATGAAGCGTGGAGACAGC-3' (SEQ.ID.No. 23)	exon 13 forward
15 6395	5'-CCTGGAGGGGTCCCCAGATG-3' (SEQ.ID.No. 24)	exon 16 reversed
6406	5'-TGCAGCCCCACGGAAGGCTC-3' (SEQ.ID.No. 25)	exon 14 forward
6506	5'-CAGGGCTCCAGGCTGCAGGC-3' (SEQ.ID.No. 26)	exon 23 reversed
6548	5'-AGGAAGAGCTGTGTGGCCTG-3' (SEQ.ID.No. 27)	exon 22 forward
6725	5'-GACGGGCCCCAGCCGGCCGCTGCAGGGGCATCCTACAC-3' (SEQ.ID.No. 28)	exon 3 forward -SfiI
20 6276	5'-GGCCCTCGAGCGGTTCTTCTTCCCTTCCAGG-3' (SEQ.ID.No. 29)	exon 29 reversed -XhoI

Determination of Similarities to Other Proteins

The SMART program (<http://smart.embl-heidelberg.de>) is searched for domain architectures of the protease and identified protein modules including a signal peptide with its
5 transmembrane region, a furin cleavage site, a metalloprotease domain, i.e. a Zn -protease catalytic site consensus sequence (HEXXH), a Met turn, a disintegrin domain, a cysteine -rich region, and thrombospondin type 1 (TSP-1) motifs (Figure 6). These modules are also shared by members of the novel ADAMTS
10 (for a disintegrin and metalloprotease with thrombospondin type 1 motif) metalloproteinase family (Tang 1999. FEBS Lett. 445:223-225; Tang 2001. Int. J. Biochem. Cell Biol. 33:33-44). The amino acid sequence of the vWF cleaving protease is aligned with all the human ADAMTS protein sequences, which are
15 listed by the human genome organization (HUGO) gene nomenclature committee
<http://www.gene.ucl.ac.uk/nomenclature/genefamily/adamts.html>
A schematic representation of the domains is shown in Figure 6. In contrast to the ADAMTS proteins our putative new member
20 of this family lacks a prodomain. However, examination of the amino acid sequences of the next five putative exons upstream of exon 1-2 showed no sequence homologies to ADAMTS proteins. In addition, no signal peptide sequences can be found on these exons. We thus named the vWF -cleaving protease ADAMTS13.
25 The deduced amino acid sequence is also compared with the EMBL protein database (<http://ww2.ebi.ac.uk>). Exons 9 to 16 correspond partly to an already submitted hypothetical 39.9 kDa protein located on chromosome 9 and termed open reading frame 8 (C9ORF8, XM 005647, GI12735207). In addition exon 26
30 to 29 correspond to the hypothetical protein DKFZp434C2322 (NM032252, GI14149974) (Wiemann et al. 2001. Genome Res. 11: 422-435).

Example 4:**Affinity purification of von Willebrand Factor (vWF)**

The peptide with the sequence AAGGILHLELLV (SEQ.ID.No. 1) is synthesized on a solid-phase support following the method of Barany et al. (1980. Solid-phase Peptide Synthesis. In: *The Peptides*. vol. 2 ,Gross, E. and Meienhofer, J. (eds.) Academic, New York, SEITEN). After cleavage and de-protection of the peptide, the peptide is purified by ion-exchange chromatography. The peptide is characterized by reverse phase HPLC on a C8 silica column with gradient elution in trifluoro acetic acid with acetonitrile. The peptide showed no major byproducts.

The peptide is solubilized in a concentration of 5 mg/mL in 0.1 molar phosphate buffer pH 7.5 and incubated with a pre-activated gel suitable for affinity chromatography (Actigel, ALD-Superflow, Sterogene). Prior to coupling of the peptide to the gel the pre-activated matrix is excessively washed with the same phosphate buffer. One volume of the pre-washed gel is then mixed with one volume of the peptide solution to be immobilized and subsequently 0.1 volume portions of a solution of 0.1 molar cyanoborohydride (NaCNBH_3) in 0.1 molar phosphate buffer pH 7.5. The gel is suspended in this solution and shaken for 15 hours at room temperature. Subsequently the gel is washed on a sinter funnel with a 10-fold volume of the phosphate buffer containing 150 mmolar NaCl and with 5 volumes of the phosphate buffer containing 2 molar NaCl. Then the gel is equilibrated with an access of 0.1 molar phosphate buffer pH 7.0.

The gel is then transferred into a chromatographic column having a dimension of diameter to gel bed height of

1:4. By determining the peptide concentration the solution of the incubation supernatant after separation from the gel and the washing solutions the amount of peptide coupled to the affinity matrix is calculated. The coupling rate is 85%.

The gel is subsequently used to purify vWF from a Factor VIII (FVIII)/vWF complex. A FVIII/vWF complex concentrate is produced according to US 4,814,435 containing vWF in a concentration of 260 U vWF:Ag/ml and a specific activity of 13.5 U vWF:Ag/mg Protein. The concentrate is diluted with 20 mM phosphate buffer pH 7.0 to a final vWF concentration of 6 U vWF:Ag/mL. A volume of 20 ml of this solution is subjected to the affinity column with immobilized peptide described above. After washing the column with 10 ml of the phosphate buffer the vWF specifically bound to the peptide ligand is eluted by a linear gradient from 0-2 mol/l NaCl in phosphate buffer at a flow rate of 1 ml / minute. Fractions of 1 ml are collected and their optical density is determined at 280 nm. All fractions are measured for their content of vWF antigen determined by a specific ELISA method (Asserachrom vWF, Boehringer, Mannheim). Measurement showed a specific peak of vWF eluting from the peptide at a NaCl concentration of 100 mmol/l, while most of the protein measured by UV-absorption eluted prior to the vWF fraction with the washing buffer. The vWF containing fractions are pooled and measured for vWF activity. The vWF in this pool had a specific activity of 95 U vWF/mg protein and is essentially free from other proteins.

Example 5:**Anti-vWF-cp polypeptide antibodies**

The peptide with the sequence AAGGILHLELLV (SEQ.ID.No. 1) is synthesized and purified as described in example 4.

5 The peptide is then used to immunize 3 months old BALB/c mice with the following protocol: A primary subcutaneous injection of 100 µg peptide antigen emulsified in Freund's complete adjuvant in 100 µl followed by intra-peritoneal boosts of 100 µg peptide antigen in phosphate buffered
10 saline at monthly intervals.

The anti-peptide titer is tested by routine ELISA method using purified peptide as screening antigen. After the final boost the spleens are taken from the mice for cell fusion. Cell fusion is carried out according to a
15 standard protocol originally described by Köhler et al. (1975, Nature 256:495-497). Anti-peptide antibodies producing hybridoma cell lines are screened by standard techniques with the purified peptide as screening antigen essentially based on a conventional ELISA methodology.
20 After cloning a cell line can be isolated with a high expression level of an antibody specific for the screening peptide with the sequence AAGGILHLELLV. This cell line is cultured on serum-free culture medium and grown to high density. The supernatant of the cell culture is harvested
25 by centrifugation to remove cells and the monoclonal antibody containing supernatant is concentrated by ultra-diafiltration and conditioned for further use.

The monoclonal antibody obtained had a high selectivity for the vWF cleaving protease as described by
30 Furlan et al. (1996, Blood 87: 4223-4234). This monoclonal antibody is immobilized to a polystyrene ELISA plate in a carbonate/bi-carbonate buffer, 0.05 molar, pH 9.6, at a

concentration of 5 µg immunoglobuline/ml overnight
(16 hours) at 4°C, with each 100 µl of coating solution per
well. The coating solution is removed from the wells and
replaced by a solution of bovine serum albumin (BSA) at a
concentration of 100 µg/ml at a volume of 100 µL per well,
for 2 hours. The BSA solution is removed and the wells are
washed with phosphate buffered saline. The pre-coated
plates are then incubated with either samples of platelet
poor plasma from healthy human plasma donors or platelet
poor plasma from patients with an unclear diagnosis of
either thrombotic thrombocytopenic purpura (TTP) or
hemolytic uremic syndrome (HUS). After incubation of the
plasma samples with the antibody coated ELISA plates as in
a routine sandwich ELISA system, after 3 hours the plasma
is removed from the wells. Wells are washed with phosphate
buffered saline and incubated with the monoclonal antibody
directed against the peptide with the sequence
AAGGILHLELLV, conjugated with horse radish peroxidase
following the method of Wilson et al. (1978. In:
Immunofluorescence and Related Staining Techniques; Knapp,
W. Holubar, K. and Wick, G (eds.), Elsevier/North Holland,
Amsterdam, 215) and detected by the OPT reagent as
described by Cathy et al, (1989. ELISA and related enzyme
immunoassays, In: *Antibodies II a practical approach*. Cathy
D (ed.), IRL Press Eynsham Oxford England, 97).

Based on the level of the samples from the healthy
human plasma donors a normal range is established. Plasmas
from patients with HUS had a vWF protease activity
equivalent to healthy humans while patients with TTP had a
decreased protease activity as confirmed by an assay based
on a different assay principle as described in WO 00/50904.

Example 6:**Cloning of the vWF cleaving protease gene**

Human salivary gland poly A+ RNA is purchased from Clontech. First strand cDNA is obtained using Expand
5 reverse transcriptase (Hoffmann La Roche) and oligo d(T) primer according to the manufacturer's instructions. PCR is performed using 5' CGGCGGGATCCTACACCTGG 3' (SEQ.ID.NO. 10) and 5' AATGGTGACTCCCAGGTCGA 3' (SEQ.ID.NO. 11) as primers with 10 ng of salivary gland cDNA as template and 10 U of
10 Hot Star Taq polymerase (Qiagen). The thermal cycling parameters are an initial incubation at 94° C for 15 minutes followed by 45 cycles of 94° C (50 sec), 50° C (50 sec), 72° C (2 min). PCR products are directly sequenced in both directions using the BigDye Terminator Cycle
15 Sequencing Ready Reaction Kit (PerkinElmer Life Science).

The obtained DNA sequence is used to scan the genomic data base using BLAST (basic local alignment search tool) programs and matched to the chromosome 9 clone RP11-224N20. DNA sequence is translated to amino acids sequence using
20 ExPASy proteomic tools. The DNA and translated amino acid sequence corresponding to 4 putative exons of chromosome 9q34 is shown in Fig. 5.

RT-PCR fragments encompassing either the pre-prosequence or the mature domains of the vWF cleaving
25 protease are cloned into vector pDrive (Qiagen) by PCR cloning. For amplification of mature vWF-cp the primer #6601 (5'-AGCGGTCTCTATGGCTGCAGGCGGCATCCTACACC-3') (SEQ.ID.NO. 30) and #6617 (5'-AGCCTCGAGCTGGCCAGACACGGAACAAAT-3') (SEQ.ID.NO. 31) are used. The resulting DNA-fragment is
30 ligated to the T-overlaps of vector pDrive. The construct comprising mature vWF-cp is called pFP H251/8. For amplification of pre-prosequence of vWF-cp the primer

#66128 (5'-GGCGAATTCATGCACCAGCGTCACCCCG- 3') (SEQ. ID. NO. 32) and #6787 (5'-ACAGCATTAATAAGCCGCC-3') (SEQ.ID.NO. 33) are used. The resulting DNA-fragment is inserted into vector pDrive. The resulting construct is called pFP H262-35/14.

Example 7

Expression of vWF cleaving protease

The eukaryotic expression vector pcDNA3.1(+) (Invitrogen) is used for the expression of the full-length vWF cleaving protease (vWF-cp) under control of the human CMV promoter.

A 4.12 kB EcoRI/XhoI fragment is excised from the plasmid pFP H251/8, the fragment encompassing the cDNA sequence encoding the mature vWF-cp from nucleotide nt 223 to 4284 (without pre-pro-sequence from nt 1 to nt 222) and inserted into the EcoRI/XhoI sites of pcDNA3.1(+). To complete the 5' -end of the cDNA to add the leader and propeptide sequence, a PCR is performed using plasmid pFP H262-35/14 which contains the cDNA sequence of vWF-cp from nt -10 (10 nt upstream from start codon ATG) to nt +824 in vector pDrive (Qiagen) as template and direct primer 6839 (5'-GATCGAATTCGCCCGCCACCATGCACCAGCGTCACCC CCG- 3') (SEQ.ID.NO. 34), harbouring the Kozak consensus sequence (underlined) for the optimal context for the recognition of the start codon, and reverse primer 3113 (5'- CGGATAACAATTTACACAGG-3') (SEQ.ID.NO. 35), which binds in the lacZ region of pDrive vector. PCR is accomplished under standard reaction conditions using HotStar DNA polymerase (Qiagen) and Q-solution (Qiagen). The amplified fragment comprising nt -10 to +824 is cut with EcoRI and AscI and used to replace the EcoRI/AscI fragment of the incomplete clone containing only

the mature sequence of vWF-cp. The latter construct encoding the complete sequence of vWF-cp called pCMV-vWFcp is further used for transfection and expression studies in mammalian cells.

5

For expression of vWF-cp, SKHep cells (ATCC) cells are transiently transfected with plasmid pCMV-vWFcp and, in parallel as a control with parental vector cDNA3.1(+), using Lipofectamine 2000 (Life Technologies, Inc).

10 Transfected cells are cultivated under standard conditions in DMEM/HAM's F12(1:1) medium (GIBCO) with 10% fetal calf serum, at a temperature of 37°C and 5% CO₂.

vWF-cp expression is analysed by Western blot, whereby
15 samples of conditioned medium and cell harvest are subjected to SDS-PAGE on a 4%stacking/6% separation gel and Western-blot analysis is performed using anti-vWF-cp TTP patient plasma containing polyclonal anti-vWF-cp antibodies and goat-anti-hu-IgG (Fab-specific AB, SIGMA). VWF-cp specific
20 bands are visualized by BCIP/NBT detection.

VWF-cp could be detected in sample of the cell lysate and seems to be mainly cell-associated. The results of the Westernblot analysis is shown in Figure 7, showing specific
25 protein band of vWF-cp at about molecular weight of about 170kD reacting with patient sera.

The cell lysate of the vWF-cp expressing cells are further tested for vWF-cp activity according to the method as
30 described by Furlan et al. (1996. Blood 87: 4235-4244) and vWF multimer analysis is performed in 1% SDS-agarose gel as described by Ruggeri et al. (1981. Blood 57: 1140-1143)

(Fig. 8). The biological activity of the vWF-cp expressed in mammalian cells could be clearly shown as high molecular weight vWF is degraded to vWF molecules having lower molecular weight (Fig. 8, lane 5).

5

Claims:

1. A vWF-cp polypeptide comprising (a) an amino acid
sequence selected from the group of SEQ ID. NO 1, SEQ
5 ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5,
or (b) an amino acid sequence having at least 80%
identity to the amino acid sequence of (a).
2. The polypeptide according to claim 1 encoding a
10 polypeptide having an amino sequence as shown in Fig.
5 or a partial sequence of at least 12 amino acids
thereof.
3. The polypeptide according to claim 1 or 2 having a
15 vWF-cp activity.
4. The polypeptide according to any of the claims 1-
3, wherein said polypeptide retains vWF cleaving
protease activity in the presence of serine protease
20 inhibitor and a calpain protease inhibitor.
5. An isolated polypeptide comprising an amino acid
sequence having at least 80% identity to the amino
acid sequence selected from the group of SEQ ID. NO 1,
25 SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID
NO. 5.
6. An isolated polypeptide comprising an amino acid
sequence selected from the group of SEQ ID. NO 1,
30 SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ
ID NO. 5.

7. A substantially pure vWF -cp polypeptide selected from the group of a polypeptide comprising (a) an amino acid sequence selected from the group of SEQ ID. NO 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and
5 SEQ ID NO. 5, or (b) an amino acid sequence having at least 80% identity to the amino acid sequence of (a).
8. A substantially pure vWF -cp polypeptide according to claim 7, wherein said polypeptide exhibiting an
10 apparent molecular weight of about 180 KD, 170 kD, 160 kD or 120 KD in SDS-PAGE analysis under reducing conditions.
9. A substantially pure vWF -cp polypeptide according to claim 7, wherein said polypeptide exhibiting an
15 apparent molecular weight of about 150 KD, 140 kD, 130 kD or 110 KD in SDS-PAGE analysis under non-reducing conditions.
10. A composition comprising a polypeptide according to
20 any of the claims 1 - 9.
11. A composition according to claim 10 further comprising a divalent metal ion selected from the
25 group of Ca^{2+} , Sr^{2+} , Ba^{2+} and Mg^{2+} .
12. A composition according to claim 10 or 11 comprising clusterin or an analog or derivative thereof having clusterin activity.
30
13. A nucleic acid molecule comprising a nucleic acid sequence encoding a vWF-cp polypeptide according to

any of the claims 1 to 7.

14. The nucleic acid molecule according to claim 13
encoding a vWF-cp polypeptide as shown in Fig. 5 or a
5 partial sequence thereof.

15. An expression vector comprising a nucleic acid
molecule according to claim 13.

10 16. A host cell comprising an expression vector
according to claim 15.

17. A method for production of a vWF-cp protease
polypeptide comprising the steps of
15 - growing a host cell according to claim 16 in a
nutrient medium under conditions to express said
polypeptide
- harvesting said polypeptide expressed and
- isolating said polypeptide.

20 18. A method of purification of vWF comprising the
steps of
- providing as a ligand a vWF-cp polypeptide according
to any of the claims 1 to 7,
25 - contacting a solution comprising vWF with said
polypeptide ligand under conditions whereby vWF is
bound to said ligand and
- recovering from said ligand purified vWF.

30 19. A method for production of anti-vWF cp
polypeptide antibodies wherein an animal is
immunized with a vWF-cp polypeptide according to any

of the claims 1 to 7 and anti-vWF-cp polypeptide antibodies are isolated from said animal.

20. A vWF-cp polypeptide binding molecule selected from
5 the group of antibodies, single chain antibodies, Fab-
or Fab'2-fragment, peptide or polypeptides with vWF
protease binding site, obtainable by a method wherein
a phage display library is screened for anti-vWF-cp
polypeptide binding molecule, the nucleic acid
10 sequence of positive clones are determined and a
nucleic acid molecule comprising the sequence is
cloned into an expression vector.
21. A method for purification of vWF -cp polypeptide
15 comprising the step of contacting a solution
comprising vWF -cp polypeptide with vWF protease
polypeptide binding molecule according to claim 20,
under conditions whereby vWF -cp polypeptide is bound
to said vWF -cp polypeptide binding molecule,
20 selectively eluting vWF -cp polypeptide from said
binding molecule and recovering purified vWF.
22. A method for detection of vWF -cp polypeptide in a
sample, wherein a solution suspected to contain vWF -
25 cp is contacted with a vWF-cp polypeptide binding
molecule according to claim 20, to allow the formation
of an vWF -cp polypeptide/ binding molecule complex
and detection said complex.
- 30 23. Use of a vWF-cp polypeptide according to any of the
claims 1 to 7 for the production of a preparation for
prophylaxis and therapy of thrombosis and

thromboembolic disease.

24. Use according to claim 23, wherein the
thromboembolic disease is thrombotic thrombocytic
5 purpura (TTP), Henoch-Schönlein purpura, preeclampsia,
neonatal thrombocytopenia or hemolyticuremic syndrome.

PURIFICATION SCHEME

1. Purification Step




Figure 1

2. Purification Step




Figure 1

3. Purification Step






Figure 1

Optional: 4. Purification Step**Figure 1**

**Figure 2**

gctgcaggcggcatcctacacctggagctgctgggtggccgtgggccccgatgtc
A A G G I L H L E L L V A V G P D V
ttccaggctcaccaggaggacacagagcgctatgtgctcaccaacctcaacatcggggca
F Q A H Q E D T E R Y V L T N L N I G A
gaactgcttcggggacccgtccctgggggctcagtttcgggtgcacctgggtgaagatgggtcat
E L L R D P S L G A Q F R V H L V K M V I
tctgacagagcctgaggggtgccccaaatatcacagccaacctcacctcgctccctgctgagc
L T E P E G A P N I T A N L T S S L L S
gtctgtgggtggagccagaccatcaaccctgaggacgacacggatcctggccatgctgac
V C G W S Q T I N P E D D T D P G H A D
ctggctcctctatatcactaggtttgacctggagttgcctgatggtaaccggcaggtgcgg
L V L Y I T R F D L E L P D G N R Q V R
ggcgtcacccagctgggcgggtgcctgctccccaacctggagctgcctcattaccgaggac
G V T Q L G G A C S P T W S C L I T E D
actggcttcgacctgggagtcaccatt
T G F D L G V T I

Figure 3




Figure 4

Figure 5A

Figure 5B

33121	P R W K V M S L G P C S A S C G L G T A R R S V A C V Q Q L D Q G Q D V E V D E A CTAGTGGAAAGTCATGTCCTTGGCCCATGTTGGCCAGCTGTGGCACTGCTAGACGCTGGTGGCCCTGTGTGACGCTCGACCAAGCCAGGACGTGGAGGTGGACGAGCGG	3340
33241	A C A A L V R P E A S V P C L I A D C T Y R W H V G T W M E C S V S C G D G I Q CCTGTGGCGCGTGGTGGCGCCGAGCCAGTGTCCCTGTCTATTGCCGACTGCACCTACCGCTGGCATGTGTGGACCTGGATGGATGTCTGTTCCTGTGGGATGGCATCCAGC	3360
33361	R R R D T C L G P Q A Q A P V P A D F C Q H L P K P V T V R G C W A G P C V G Q GCCGCGTGACACCTGCTCGGACCCAGGCCAGGCGCTGTGGCAGCTGATTTCTGCCAGCACTTGGCCAAAGCGGTGACTGTGCGTGGCTGTGGCTGGGCGCTGTGTGGACAGG	3380
33481	G T P S L V P H E E A A P G R T T A T P A G A S L E W S Q A R G L L F S P A P GTACGCCAGCCTGGTGCCCCACGAAGAAGCCGCTGTCTCAGGAGGACACAGCCACCCCTGCTGTGGCTCTCCCTGGAGTGTCCAGGCCGGGGCTGCTCTCTCTCCCGGCTCCCC	3400
33601	Q P R R L L P G P Q E N S V Q S S A C G R Q H L E P T G T I D M R G P G Q A D C AGCCTCGGCGGCTCTCTGCCCGGGCCCCAGGAATACTCAGTGCAGTCCAGTGCCTGTGGCAGGACGACCTTCAGCCAAACAGGAACCATTCACATGCCAGGCCCGCAGGCAGCTGTG	3420
33721	A V A I G R P L G E V V T L R V L E S S L N C S A G D M L L L W G R L T W R K M CAGTGGCCATTGGGGGCCCCCTCGGGAGGTGGTGAACCTCCGCTCTCTCAGAGTCTCTCAACTGCGGGGGAATGTGTGCTCTTTGGGCGCGCTACCTGGAGGAAGATGT	3440
33841	C R K L L D M T F S S K T N T L V V R Q R C G R P G G V L L R Y G S Q L A P E GCAGGAAGCTGTGGACATGACTTTCAGCTCCAAGACCAACACGCTGGTGTGAGCAGCGCTTCGGCGCGCCAGGAGTGGGGTGTCTCTCGGTATGGAGCAGCCAGCTTCTCTCTGAAA	3460
33961	T F Y R E C D M Q L F G P W G E I V S P S L S P A T S N A G G C R L F I N V A P CCTTCTACAGAGAAATGTACATGCAGCTCTTTGGGCCCTCGGTGAAATCTGTAGCCCTCGCTGATTCAGCCACAGTAATGACGGGGTGTCCGGCTCTTCAATTAATGTGGCTCCGC	3480
34081	H A R I A I H A L A T N M G A G T E G A N A S Y I L I R D T H S L R T T A F H G ACGCAGGAATGCCATCCATCCCTGGCCACCAACATGGCGCTGGACCGAGGAGCCATCCAGCTACATCTTATCCGGGACACCCACAGCTTGGAGCACCAGCGTTCATCTGGC	3420
34201	Q Q V L Y W E S E S S Q A E M E F S E G F L K A Q A S L R G Q Y W T L Q S W V P AGCAGGTGCTACTTGGAGTCAGAGAGCAGCGGTGAGATGAGTTTCTGAAGGCTCAGGCCAGCTTGGGGGCGAGTCTGAGCCCTTCCAAATCATGGGTACCGG	3440
34321	E M Q D P Q S W K G E G T * AGATCAGGACCTTCAGTCCCTGGAGGGAAGGAACCTTCAGGCTCATTGAACATTTGTTCCTGCTCTGGCCAGCCCTGGAGGTTGACCCCTGGTCTCAGTCTTCCAATTCCAA	3460
34441	CTTTTTCCAATCTTAGCTATCTACTTCTAGACTCTTCTCCAAATCTCCAAAAGGCTAGGGGTTGGAGGTGGGACTCTTGAAAAAGCAGCCCCCATTTCTCTGGGTACCAATAAATAACA	3480
34561	TCAGGCGCAAAAAAATAAAAAA 4585	3500

Figure 5C





Figure 6

**Figure 7**




Figure 8

SEQUENCE LISTING

5 <110> Baxter AG
 <120> von Willebrand factor(vWf)cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide
 10 <130> FA247
 <140>
 <141>
 15 <150> 09/721,254
 <151> 2000-11-22
 <150> 09/833,328
 <151> 2001-04-12
 20 <160> 35
 <170> PatentIn Ver. 2.1
 25 <210> 1
 <211> 12
 <212> PRT
 <213> Homo sapiens
 30 <400> 1
 Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val
 1 5 10
 35 <210> 2
 <211> 15
 <212> PRT
 <213> Homo sapiens
 40 <400> 2
 Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val Gly
 1 5 10 15
 45 <210> 3
 <211> 148
 <212> PRT
 <213> Homo sapiens
 50 <400> 3
 Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val Gly Pro
 1 5 10 15
 Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg Tyr Val Leu Thr
 20 25 30
 55 Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp Pro Ser Leu Gly Ala
 35 40 45

Gln Phe Arg Val His Leu Val Lys Met Val Ile Leu Thr Glu Pro Glu
 50 55 60

5 Gly Ala Pro Asn Ile Thr Ala Asn Leu Thr Ser Ser Leu Leu Ser Val
 65 70 75 80

Cys Gly Trp Ser Gln Thr Ile Asn Pro Glu Asp Asp Thr Asp Pro Gly
 85 90 95

10 His Ala Asp Leu Val Leu Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro
 100 105 110

Asp Gly Asn Arg Gln Val Arg Gly Val Thr Gln Leu Gly Gly Ala Cys
 115 120 125

Ser Pro Thr Trp Ser Cys Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu
 130 135 140

20 Gly Val Thr Ile
 145

<210> 4
 25 <211> 1353
 <212> PRT
 <213> Homo sapiens

<400> 4
 30 Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val Gly Pro
 1 5 10 15

Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg Tyr Val Leu Thr
 20 25 30

35 Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp Pro Ser Leu Gly Ala
 35 40 45

Gln Phe Arg Val His Leu Val Lys Met Val Ile Leu Thr Glu Pro Glu
 40 50 55 60

Gly Ala Pro Asn Ile Thr Ala Asn Leu Thr Ser Ser Leu Leu Ser Val
 65 70 75 80

45 Cys Gly Trp Ser Gln Thr Ile Asn Pro Glu Asp Asp Thr Asp Pro Gly
 85 90 95

His Ala Asp Leu Val Leu Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro
 100 105 110

50 Asp Gly Asn Arg Gln Val Arg Gly Val Thr Gln Leu Gly Gly Ala Cys
 115 120 125

Ser Pro Thr Trp Ser Cys Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu
 130 135 140

55

	Gly Val Thr Ile Ala His Glu Ile Gly His Ser Phe Gly Leu Glu His	
	145	150 155 160
5	Asp Gly Ala Pro Gly Ser Gly Cys Gly Pro Ser Gly His Val Met Ala	
		165 170 175
	Ser Asp Gly Ala Ala Pro Arg Ala Gly Leu Ala Trp Ser Pro Cys Ser	
		180 185 190
10	Arg Arg Gln Leu Leu Ser Leu Leu Ser Ala Gly Arg Ala Arg Cys Val	
		195 200 205
	Trp Asp Pro Pro Arg Pro Gln Pro Gly Ser Ala Gly His Pro Pro Asp	
		210 215 220
15	Ala Gln Pro Gly Leu Tyr Tyr Ser Ala Asn Glu Gln Cys Arg Val Ala	
		225 230 235 240
20	Phe Gly Pro Lys Ala Val Ala Cys Thr Phe Ala Arg Glu His Leu Asp	
		245 250 255
	Met Cys Gln Ala Leu Ser Cys His Thr Asp Pro Leu Asp Gln Ser Ser	
		260 265 270
25	Cys Ser Arg Leu Leu Val Pro Leu Leu Asp Gly Thr Glu Cys Gly Val	
		275 280 285
	Glu Lys Trp Cys Ser Lys Gly Arg Cys Arg Ser Leu Val Glu Leu Thr	
		290 295 300
30	Pro Ile Ala Ala Val His Gly Arg Trp Ser Ser Trp Gly Pro Arg Ser	
		305 310 315 320
	Pro Cys Ser Arg Ser Cys Gly Gly Gly Val Val Thr Arg Arg Arg Gln	
35		325 330 335
	Cys Asn Asn Pro Arg Pro Ala Phe Gly Gly Arg Ala Cys Val Gly Ala	
		340 345 350
40	Asp Leu Gln Ala Glu Met Cys Asn Thr Gln Ala Cys Glu Lys Thr Gln	
		355 360 365
	Leu Glu Phe Met Ser Gln Gln Cys Ala Arg Thr Asp Gly Gln Pro Leu	
		370 375 380
45	Arg Ser Ser Pro Gly Gly Ala Ser Phe Tyr His Trp Gly Ala Ala Val	
		385 390 395 400
	Pro His Ser Gln Gly Asp Ala Leu Cys Arg His Met Cys Arg Ala Ile	
50		405 410 415
	Gly Glu Ser Phe Ile Met Lys Arg Gly Asp Ser Phe Leu Asp Gly Thr	
		420 425 430
55	Arg Cys Met Pro Ser Gly Pro Arg Glu Asp Gly Thr Leu Ser Leu Cys	
		435 440 445

	Val	Ser	Gly	Ser	Cys	Arg	Thr	Phe	Gly	Cys	Asp	Gly	Arg	Met	Asp	Ser	
	450						455					460					
5	Gln	Gln	Val	Trp	Asp	Arg	Cys	Gln	Val	Cys	Gly	Gly	Asp	Asn	Ser	Thr	
	465					470					475					480	
	Cys	Ser	Pro	Arg	Lys	Gly	Ser	Phe	Thr	Ala	Gly	Arg	Ala	Arg	Glu	Tyr	
					485					490					495		
10	Val	Thr	Phe	Leu	Thr	Val	Thr	Pro	Asn	Leu	Thr	Ser	Val	Tyr	Ile	Ala	
				500					505					510			
	Asn	His	Arg	Pro	Leu	Phe	Thr	His	Leu	Ala	Val	Arg	Ile	Gly	Gly	Arg	
			515					520					525				
15	Tyr	Val	Val	Ala	Gly	Lys	Met	Ser	Ile	Ser	Pro	Asn	Thr	Thr	Tyr	Pro	
	530						535					540					
20	Ser	Leu	Leu	Glu	Asp	Gly	Arg	Val	Glu	Tyr	Arg	Val	Ala	Leu	Thr	Glu	
	545					550					555					560	
	Asp	Arg	Leu	Pro	Arg	Leu	Glu	Glu	Ile	Arg	Ile	Trp	Gly	Pro	Leu	Gln	
					565					570					575		
25	Glu	Asp	Ala	Asp	Ile	Gln	Val	Tyr	Arg	Arg	Tyr	Gly	Glu	Glu	Tyr	Gly	
				580					585					590			
	Asn	Leu	Thr	Arg	Pro	Asp	Ile	Thr	Phe	Thr	Tyr	Phe	Gln	Pro	Lys	Pro	
			595					600					605				
30	Arg	Gln	Ala	Trp	Val	Trp	Ala	Ala	Val	Arg	Gly	Pro	Cys	Ser	Val	Ser	
		610					615					620					
35	Cys	Gly	Ala	Gly	Leu	Arg	Trp	Val	Asn	Tyr	Ser	Cys	Leu	Asp	Gln	Ala	
	625					630					635					640	
	Arg	Lys	Glu	Leu	Val	Glu	Thr	Val	Gln	Cys	Gln	Gly	Ser	Gln	Gln	Pro	
				645					650						655		
40	Pro	Ala	Trp	Pro	Glu	Ala	Cys	Val	Leu	Glu	Pro	Cys	Pro	Pro	Tyr	Trp	
				660					665						670		
	Ala	Val	Gly	Asp	Phe	Gly	Pro	Cys	Ser	Ala	Ser	Cys	Gly	Gly	Gly	Leu	
		675					680						685				
45	Arg	Glu	Arg	Pro	Val	Arg	Cys	Val	Glu	Ala	Gln	Gly	Ser	Leu	Leu	Lys	
		690					695					700					
50	Thr	Leu	Pro	Pro	Ala	Arg	Cys	Arg	Ala	Gly	Ala	Gln	Gln	Pro	Ala	Val	
	705					710					715					720	
	Ala	Leu	Glu	Thr	Cys	Asn	Pro	Gln	Pro	Cys	Pro	Ala	Arg	Trp	Glu	Val	
				725					730					735			
55	Ser	Glu	Pro	Ser	Ser	Cys	Thr	Ser	Ala	Gly	Gly	Ala	Gly	Leu	Ala	Leu	
				740					745					750			

Glu Asn Glu Thr Cys Val Pro Gly Ala Asp Gly Leu Glu Ala Pro Val
 755 760 765
 5 Thr Glu Gly Pro Gly Ser Val Asp Glu Lys Leu Pro Ala Pro Glu Pro
 770 775 780
 Cys Val Gly Met Ser Cys Pro Pro Gly Trp Gly His Leu Asp Ala Thr
 785 790 795 800
 10 Ser Ala Gly Glu Lys Ala Pro Ser Pro Trp Gly Ser Ile Arg Thr Gly
 805 810 815
 Ala Gln Ala Ala His Val Trp Thr Pro Ala Ala Gly Ser Cys Ser Val
 820 825 830
 15 Ser Cys Gly Arg Gly Leu Met Glu Leu Arg Phe Leu Cys Met Asp Ser
 835 840 845
 20 Ala Leu Arg Val Pro Val Gln Glu Glu Leu Cys Gly Leu Ala Ser Lys
 850 855 860
 Pro Gly Ser Arg Arg Glu Val Cys Gln Ala Val Pro Cys Pro Ala Arg
 865 870 875 880
 25 Trp Gln Tyr Lys Leu Ala Ala Cys Ser Val Ser Cys Gly Arg Gly Val
 885 890 895
 Val Arg Arg Ile Leu Tyr Cys Ala Arg Ala His Gly Glu Asp Asp Gly
 900 905 910
 30 Glu Glu Ile Leu Leu Asp Thr Gln Cys Gln Gly Leu Pro Arg Pro Glu
 915 920 925
 Pro Gln Glu Ala Cys Ser Leu Glu Pro Cys Pro Pro Arg Trp Lys Val
 930 935 940
 35 Met Ser Leu Gly Pro Cys Ser Ala Ser Cys Gly Leu Gly Thr Ala Arg
 945 950 955 960
 40 Arg Ser Val Ala Cys Val Gln Leu Asp Gln Gly Gln Asp Val Glu Val
 965 970 975
 Asp Glu Ala Ala Cys Ala Ala Leu Val Arg Pro Glu Ala Ser Val Pro
 980 985 990
 45 Cys Leu Ile Ala Asp Cys Thr Tyr Arg Trp His Val Gly Thr Trp Met
 995 1000 1005
 50 Glu Cys Ser Val Ser Cys Gly Asp Gly Ile Gln Arg Arg Arg Asp Thr
 1010 1015 1020
 Cys Leu Gly Pro Gln Ala Gln Ala Pro Val Pro Ala Asp Phe Cys Gln
 1025 1030 1035 1040
 55 His Leu Pro Lys Pro Val Thr Val Arg Gly Cys Trp Ala Gly Pro Cys
 1045 1050 1055

Val Gly Gln Gly Thr Pro Ser Leu Val Pro His Glu Glu Ala Ala Ala
 1060 1065 1070
 5 Pro Gly Arg Thr Thr Ala Thr Pro Ala Gly Ala Ser Leu Glu Trp Ser
 1075 1080 1085
 Gln Ala Arg Gly Leu Leu Phe Ser Pro Ala Pro Gln Pro Arg Arg Leu
 1090 1095 1100
 10 Leu Pro Gly Pro Gln Glu Asn Ser Val Gln Ser Ser Ala Cys Gly Arg
 1105 1110 1115 1120
 Gln His Leu Glu Pro Thr Gly Thr Ile Asp Met Arg Gly Pro Gly Gln
 1125 1130 1135
 15 Ala Asp Cys Ala Val Ala Ile Gly Arg Pro Leu Gly Glu Val Val Thr
 1140 1145 1150
 20 Leu Arg Val Leu Glu Ser Ser Leu Asn Cys Ser Ala Gly Asp Met Leu
 1155 1160 1165
 Leu Leu Trp Gly Arg Leu Thr Trp Arg Lys Met Cys Arg Lys Leu Leu
 1170 1175 1180
 25 Asp Met Thr Phe Ser Ser Lys Thr Asn Thr Leu Val Val Arg Gln Arg
 1185 1190 1195 1200
 Cys Gly Arg Pro Gly Gly Gly Val Leu Leu Arg Tyr Gly Ser Gln Leu
 1205 1210 1215
 30 Ala Pro Glu Thr Phe Tyr Arg Glu Cys Asp Met Gln Leu Phe Gly Pro
 1220 1225 1230
 35 Trp Gly Glu Ile Val Ser Pro Ser Leu Ser Pro Ala Thr Ser Asn Ala
 1235 1240 1245
 Gly Gly Cys Arg Leu Phe Ile Asn Val Ala Pro His Ala Arg Ile Ala
 1250 1255 1260
 40 Ile His Ala Leu Ala Thr Asn Met Gly Ala Gly Thr Glu Gly Ala Asn
 1265 1270 1275 1280
 Ala Ser Tyr Ile Leu Ile Arg Asp Thr His Ser Leu Arg Thr Thr Ala
 1285 1290 1295
 45 Phe His Gly Gln Gln Val Leu Tyr Trp Glu Ser Glu Ser Ser Gln Ala
 1300 1305 1310
 50 Glu Met Glu Phe Ser Glu Gly Phe Leu Lys Ala Gln Ala Ser Leu Arg
 1315 1320 1325
 Gly Gln Tyr Trp Thr Leu Gln Ser Trp Val Pro Glu Met Gln Asp Pro
 1330 1335 1340
 55 Gln Ser Trp Lys Gly Lys Glu Gly Thr
 1345 1350

5
 <210> 5
 <211> 1427
 <212> PRT
 <213> Homo sapiens

10
 <400> 5
 Met His Gln Arg His Pro Arg Ala Arg Cys Pro Pro Leu Cys Val Ala
 1 5 10 15

15
 Gly Ile Leu Ala Cys Gly Phe Leu Leu Gly Cys Trp Gly Pro Ser His
 20 25 30

20
 Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala Val Ser Ser
 35 40 45

25
 Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro Pro Ser Pro Gly
 50 55 60

30
 Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg Ala Ala Gly Gly Ile Leu
 65 70 75 80

35
 His Leu Glu Leu Leu Val Ala Val Gly Pro Asp Val Phe Gln Ala His
 85 90 95

40
 Gln Glu Asp Thr Glu Arg Tyr Val Leu Thr Asn Leu Asn Ile Gly Ala
 100 105 110

45
 Glu Leu Leu Arg Asp Pro Ser Leu Gly Ala Gln Phe Arg Val His Leu
 115 120 125

50
 Val Lys Met Val Ile Leu Thr Glu Pro Glu Gly Ala Pro Asn Ile Thr
 130 135 140

55
 Ala Asn Leu Thr Ser Ser Leu Leu Ser Val Cys Gly Trp Ser Gln Thr
 145 150 155 160

60
 Ile Asn Pro Glu Asp Asp Thr Asp Pro Gly His Ala Asp Leu Val Leu
 165 170 175

65
 Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro Asp Gly Asn Arg Gln Val
 180 185 190

70
 Arg Gly Val Thr Gln Leu Gly Gly Ala Cys Ser Pro Thr Trp Ser Cys
 195 200 205

75
 Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu Gly Val Thr Ile Ala His
 210 215 220

80
 Glu Ile Gly His Ser Phe Gly Leu Glu His Asp Gly Ala Pro Gly Ser
 225 230 235 240

Gly Cys Gly Pro Ser Gly His Val Met Ala Ser Asp Gly Ala Ala Pro
 245 250 255
 5 Arg Ala Gly Leu Ala Trp Ser Pro Cys Ser Arg Arg Gln Leu Leu Ser
 260 265 270
 Leu Leu Ser Ala Gly Arg Ala Arg Cys Val Trp Asp Pro Pro Arg Pro
 275 280 285
 10 Gln Pro Gly Ser Ala Gly His Pro Pro Asp Ala Gln Pro Gly Leu Tyr
 290 295 300
 Tyr Ser Ala Asn Glu Gln Cys Arg Val Ala Phe Gly Pro Lys Ala Val
 305 310 315 320
 15 Ala Cys Thr Phe Ala Arg Glu His Leu Asp Met Cys Gln Ala Leu Ser
 325 330 335
 20 Cys His Thr Asp Pro Leu Asp Gln Ser Ser Cys Ser Arg Leu Leu Val
 340 345 350
 Pro Leu Leu Asp Gly Thr Glu Cys Gly Val Glu Lys Trp Cys Ser Lys
 355 360 365
 25 Gly Arg Cys Arg Ser Leu Val Glu Leu Thr Pro Ile Ala Ala Val His
 370 375 380
 Gly Arg Trp Ser Ser Trp Gly Pro Arg Ser Pro Cys Ser Arg Ser Cys
 385 390 395 400
 30 Gly Gly Gly Val Val Thr Arg Arg Arg Gln Cys Asn Asn Pro Arg Pro
 405 410 415
 35 Ala Phe Gly Gly Arg Ala Cys Val Gly Ala Asp Leu Gln Ala Glu Met
 420 425 430
 Cys Asn Thr Gln Ala Cys Glu Lys Thr Gln Leu Glu Phe Met Ser Gln
 435 440 445
 40 Gln Cys Ala Arg Thr Asp Gly Gln Pro Leu Arg Ser Ser Pro Gly Gly
 450 455 460
 Ala Ser Phe Tyr His Trp Gly Ala Ala Val Pro His Ser Gln Gly Asp
 465 470 475 480
 45 Ala Leu Cys Arg His Met Cys Arg Ala Ile Gly Glu Ser Phe Ile Met
 485 490 495
 50 Lys Arg Gly Asp Ser Phe Leu Asp Gly Thr Arg Cys Met Pro Ser Gly
 500 505 510
 Pro Arg Glu Asp Gly Thr Leu Ser Leu Cys Val Ser Gly Ser Cys Arg
 515 520 525
 55 Thr Phe Gly Cys Asp Gly Arg Met Asp Ser Gln Gln Val Trp Asp Arg
 530 535 540

	Cys	Gln	Val	Cys	Gly	Gly	Asp	Asn	Ser	Thr	Cys	Ser	Pro	Arg	Lys	Gly	
	545					550					555					560	
5	Ser	Phe	Thr	Ala	Gly	Arg	Ala	Arg	Glu	Tyr	Val	Thr	Phe	Leu	Thr	Val	
					565					570					575		
	Thr	Pro	Asn	Leu	Thr	Ser	Val	Tyr	Ile	Ala	Asn	His	Arg	Pro	Leu	Phe	
				580					585					590			
10	Thr	His	Leu	Ala	Val	Arg	Ile	Gly	Gly	Arg	Tyr	Val	Val	Ala	Gly	Lys	
			595					600					605				
	Met	Ser	Ile	Ser	Pro	Asn	Thr	Thr	Tyr	Pro	Ser	Leu	Leu	Glu	Asp	Gly	
15		610					615					620					
	Arg	Val	Glu	Tyr	Arg	Val	Ala	Leu	Thr	Glu	Asp	Arg	Leu	Pro	Arg	Leu	
	625					630					635					640	
20	Glu	Glu	Ile	Arg	Ile	Trp	Gly	Pro	Leu	Gln	Glu	Asp	Ala	Asp	Ile	Gln	
					645					650					655		
	Val	Tyr	Arg	Arg	Tyr	Gly	Glu	Glu	Tyr	Gly	Asn	Leu	Thr	Arg	Pro	Asp	
				660					665					670			
25	Ile	Thr	Phe	Thr	Tyr	Phe	Gln	Pro	Lys	Pro	Arg	Gln	Ala	Trp	Val	Trp	
			675					680					685				
	Ala	Ala	Val	Arg	Gly	Pro	Cys	Ser	Val	Ser	Cys	Gly	Ala	Gly	Leu	Arg	
30		690					695					700					
	Trp	Val	Asn	Tyr	Ser	Cys	Leu	Asp	Gln	Ala	Arg	Lys	Glu	Leu	Val	Glu	
	705					710					715					720	
35	Thr	Val	Gln	Cys	Gln	Gly	Ser	Gln	Gln	Pro	Pro	Ala	Trp	Pro	Glu	Ala	
				725						730					735		
	Cys	Val	Leu	Glu	Pro	Cys	Pro	Pro	Tyr	Trp	Ala	Val	Gly	Asp	Phe	Gly	
			740						745					750			
40	Pro	Cys	Ser	Ala	Ser	Cys	Gly	Gly	Gly	Leu	Arg	Glu	Arg	Pro	Val	Arg	
		755						760					765				
	Cys	Val	Glu	Ala	Gln	Gly	Ser	Leu	Leu	Lys	Thr	Leu	Pro	Pro	Ala	Arg	
45		770					775					780					
	Cys	Arg	Ala	Gly	Ala	Gln	Gln	Pro	Ala	Val	Ala	Leu	Glu	Thr	Cys	Asn	
	785					790					795					800	
50	Pro	Gln	Pro	Cys	Pro	Ala	Arg	Trp	Glu	Val	Ser	Glu	Pro	Ser	Ser	Cys	
				805						810					815		
	Thr	Ser	Ala	Gly	Gly	Ala	Gly	Leu	Ala	Leu	Glu	Asn	Glu	Thr	Cys	Val	
			820					825						830			
55	Pro	Gly	Ala	Asp	Gly	Leu	Glu	Ala	Pro	Val	Thr	Glu	Gly	Pro	Gly	Ser	
		835						840					845				

	Val	Asp	Glu	Lys	Leu	Pro	Ala	Pro	Glu	Pro	Cys	Val	Gly	Met	Ser	Cys	
	850						855					860					
5	Pro	Pro	Gly	Trp	Gly	His	Leu	Asp	Ala	Thr	Ser	Ala	Gly	Glu	Lys	Ala	
	865					870					875					880	
	Pro	Ser	Pro	Trp	Gly	Ser	Ile	Arg	Thr	Gly	Ala	Gln	Ala	Ala	His	Val	
					885					890					895		
10	Trp	Thr	Pro	Ala	Ala	Gly	Ser	Cys	Ser	Val	Ser	Cys	Gly	Arg	Gly	Leu	
				900					905					910			
	Met	Glu	Leu	Arg	Phe	Leu	Cys	Met	Asp	Ser	Ala	Leu	Arg	Val	Pro	Val	
15		915						920					925				
	Gln	Glu	Glu	Leu	Cys	Gly	Leu	Ala	Ser	Lys	Pro	Gly	Ser	Arg	Arg	Glu	
	930						935					940					
20	Val	Cys	Gln	Ala	Val	Pro	Cys	Pro	Ala	Arg	Trp	Gln	Tyr	Lys	Leu	Ala	
	945					950					955					960	
	Ala	Cys	Ser	Val	Ser	Cys	Gly	Arg	Gly	Val	Val	Arg	Arg	Ile	Leu	Tyr	
					965					970					975		
25	Cys	Ala	Arg	Ala	His	Gly	Glu	Asp	Asp	Gly	Glu	Glu	Ile	Leu	Leu	Asp	
				980					985					990			
	Thr	Gln	Cys	Gln	Gly	Leu	Pro	Arg	Pro	Glu	Pro	Gln	Glu	Ala	Cys	Ser	
30		995						1000					1005				
	Leu	Glu	Pro	Cys	Pro	Pro	Arg	Trp	Lys	Val	Met	Ser	Leu	Gly	Pro	Cys	
	1010						1015				1020						
35	Ser	Ala	Ser	Cys	Gly	Leu	Gly	Thr	Ala	Arg	Arg	Ser	Val	Ala	Cys	Val	
	1025					1030				1035						1040	
	Gln	Leu	Asp	Gln	Gly	Gln	Asp	Val	Glu	Val	Asp	Glu	Ala	Ala	Cys	Ala	
				1045					1050						1055		
40	Ala	Leu	Val	Arg	Pro	Glu	Ala	Ser	Val	Pro	Cys	Leu	Ile	Ala	Asp	Cys	
				1060					1065					1070			
	Thr	Tyr	Arg	Trp	His	Val	Gly	Thr	Trp	Met	Glu	Cys	Ser	Val	Ser	Cys	
45		1075					1080					1085					
	Gly	Asp	Gly	Ile	Gln	Arg	Arg	Arg	Asp	Thr	Cys	Leu	Gly	Pro	Gln	Ala	
	1090					1095					1100						
50	Gln	Ala	Pro	Val	Pro	Ala	Asp	Phe	Cys	Gln	His	Leu	Pro	Lys	Pro	Val	
	1105					1110				1115						1120	
	Thr	Val	Arg	Gly	Cys	Trp	Ala	Gly	Pro	Cys	Val	Gly	Gln	Gly	Thr	Pro	
				1125					1130					1135			
55	Ser	Leu	Val	Pro	His	Glu	Glu	Ala	Ala	Ala	Pro	Gly	Arg	Thr	Thr	Ala	
				1140				1145					1150				

Thr Pro Ala Gly Ala Ser Leu Glu Trp Ser Gln Ala Arg Gly Leu Leu
 1155 1160 1165
 5 Phe Ser Pro Ala Pro Gln Pro Arg Arg Leu Leu Pro Gly Pro Gln Glu
 1170 1175 1180
 Asn Ser Val Gln Ser Ser Ala Cys Gly Arg Gln His Leu Glu Pro Thr
 1185 1190 1195 1200
 10 Gly Thr Ile Asp Met Arg Gly Pro Gly Gln Ala Asp Cys Ala Val Ala
 1205 1210 1215
 Ile Gly Arg Pro Leu Gly Glu Val Val Thr Leu Arg Val Leu Glu Ser
 1220 1225 1230
 15 Ser Leu Asn Cys Ser Ala Gly Asp Met Leu Leu Leu Trp Gly Arg Leu
 1235 1240 1245
 20 Thr Trp Arg Lys Met Cys Arg Lys Leu Leu Asp Met Thr Phe Ser Ser
 1250 1255 1260
 Lys Thr Asn Thr Leu Val Val Arg Gln Arg Cys Gly Arg Pro Gly Gly
 1265 1270 1275 1280
 25 Gly Val Leu Leu Arg Tyr Gly Ser Gln Leu Ala Pro Glu Thr Phe Tyr
 1285 1290 1295
 Arg Glu Cys Asp Met Gln Leu Phe Gly Pro Trp Gly Glu Ile Val Ser
 1300 1305 1310
 30 Pro Ser Leu Ser Pro Ala Thr Ser Asn Ala Gly Gly Cys Arg Leu Phe
 1315 1320 1325
 Ile Asn Val Ala Pro His Ala Arg Ile Ala Ile His Ala Leu Ala Thr
 1330 1335 1340
 Asn Met Gly Ala Gly Thr Glu Gly Ala Asn Ala Ser Tyr Ile Leu Ile
 1345 1350 1355 1360
 40 Arg Asp Thr His Ser Leu Arg Thr Thr Ala Phe His Gly Gln Gln Val
 1365 1370 1375
 Leu Tyr Trp Glu Ser Glu Ser Ser Gln Ala Glu Met Glu Phe Ser Glu
 1380 1385 1390
 45 Gly Phe Leu Lys Ala Gln Ala Ser Leu Arg Gly Gln Tyr Trp Thr Leu
 1395 1400 1405
 50 Gln Ser Trp Val Pro Glu Met Gln Asp Pro Gln Ser Trp Lys Gly Lys
 1410 1415 1420
 Glu Gly Thr
 1425
 55

<210> 6
 <211> 4585
 <212> DNA
 <213> Homo sapiens

5

<400> 6

```

cccattccat actgaccaga ttcccagtc ccaaggcccc ctctcactcc gctccactcc 60
tcgggctggc tctcctgagg atgcaccagc gtcacccccg ggcaagatgc cctccctctt 120
gtgtggccgg aatccttgcc tgtggctttc tctgggctg ctggggaccc tcccatthcc 180
10 agcagagttg tcttcaggct ttggagccac aggcctgtgc ttcttacttg agccctgggtg 240
ctcccttaaa aggcgcgcct ccttcccttg gcttcagag gcagaggcag aggcagaggc 300
gggctgcagg cggcatccta cacctggagc tgctgggtgc cgtgggcccc gatgtcttcc 360
aggctcacca ggaggacaca gagcgtatg tgctcaccaa cctcaacatc ggggcagaac 420
tgcttcggga ccgctccctg ggggctcagt ttgggtgca cctgggtgaag atggctatcc 480
15 tgacagagcc tgagggtgct ccaaatatca cagccaacct cacctcgtcc ctgctgagcg 540
tctgtgggtg gagccagacc atcaaccctg aggacgacac ggatcctggc catgctgacc 600
tggtcctcta tatcactagg tttgacctg agttgcctga tggtaaccgg caggtgcggg 660
gcgtcaccca gctgggcggg gcctgctccc caacctggag ctgcctcatt accgaggaca 720
ctggcttoga cctgggagtc accattgccc atgagattgg gcacagcttc ggctgggagc 780
20 acgacgggac gcccggcagc ggctggggcc ccagcggaca cgtgatggct tcggacggcg 840
ccgcgccccg ccgcggcctc gcctggctcc cctgcagccg ccggcagctg ctgagcctgc 900
tcagcgcagg acgggcgcgc tcgctgtggg accgcgcgcg gcctcaacct gggctcgcgg 960
ggcaccgcgc ggatgcgcag cctggcctct actacagcgc caacgagcag tgccgcgtgg 1020
ccttcggccc caaggctgtc gcctgcacct tcgccaggga gcacctggat atgtgccagg 1080
25 cctctcctg ccacacagac ccgctggacc aaagcagctg cagccgcctc ctggttctc 1140
tctgggatgg gacagaatgt ggctgggaga agtgggtgct caagggtcgc tgccgctccc 1200
tggtggagct gacccccata gcagcagtg atgggcctg gtctagctgg ggtccccgaa 1260
gtccttgctc ccgctcctgc ggaggaggtg tggtcaccag gaggcggcag tgcaacaacc 1320
ccagacctgc ctttgggggg cgtgcatgtg ttggtgctga cctccaggcc gagatgtgca 1380
30 aactcagggc ctgcgagaag acccagctgg agttcatgtc gcaacagtgc gccaggaccg 1440
acggccagcc gctgcgctcc tcccctggcg ggcctcctt ctaccttg gggtgctgtg 1500
taccacacag ccaaggggat gctctgtgca gacacatgtg ccgggccatt ggcgagagct 1560
tcatcatgaa gctgggagac agcttctctg atgggacccg gtgtatgcca agtggcccc 1620
gggaggacgg gacctgagc ctgtgtgtgt cgggcagctg caggacattt ggctgtgatg 1680
35 gtaggatgga ctccagcag gtatgggaca ggtgccaggt gtgtgtggg gacaacagca 1740
cgtgcagccc acggaagggc tctttcacag ctggcagagc gagagaatat gtcacgtttc 1800
tgacagttac cccaacctg accagtgtct acattgccaa ccacaggcct ctcttcacac 1860
acttggcggg gaggatcgga gggcgctatg tctggctgg gaagatgagc atctcccta 1920
acaccaccta cccctccctc ctggaggatg gtctgtgca gtacagagtg gccctcaccg 1980
40 aggaccggct gcccgcctg gaggagatcc gcctctggg acccctccag gaagatgctg 2040

```

5 acatccaggt ttacaggcgg tatggcgagg agtatggcaa cctcaccgcg ccagacatca 2100
 ccttcaccta cttccagcct aagccacggc aggcctgggt gtgggocgct gtgcgtgggc 2160
 cctgctcggt gagctgtggg gcagggctgc gctgggtaaa ctacagctgc ctggaccagg 2220
 ccaggaagga gttggtggag actgtccagt gccaaaggag ccagcagcca ccagcgtggc 2280
 10 cagaggcctg cgtgctcgaa cctgccctc cctactgggc ggtgggagac ttcggcccat 2340
 gcagcgctc ctgtgggggt ggctgcggg agcgccaggt gcgctgcgtg gaggcccagg 2400
 gcagcctcct gaagacattg ccccagccc ggtgcagagc agggggccag cagccagctg 2460
 tggcgctgga aacctgcaac cccagccct gccctgccag gtgggaggtg tcagagccca 2520
 gctcatgcac atcagctggg ggagcaggcc tggccttga gaacgagacc tgtgtgccag 2580
 15 gggcagatgg cctggaggct ccagtgactg aggggcctgg ctccgtagat gagaagctgc 2640
 ctgccctga gccctgtgtc gggatgtcat gtccctcagg ctggggccat ctggatgcca 2700
 cctctgcagg ggagaaggct cctccocat ggggcagcat caggacgggg gctcaagctg 2760
 cacacgtgtg gaccctgcg gcagggtcgt gctccgtctc ctgcgggcga ggtctgatgg 2820
 agctgcgttt cctgtgcatg gactctgccc tcagggtgcc tgtccaggaa gagctgtgtg 2880
 20 gcctggcaag caagcctggg agcggcggg aggtctgcca ggctgtcccg tgccctgctc 2940
 ggtggcagta caagctggcg gcctgcagcg tgagctgtgg gagaggggtc gtgcggagga 3000
 tcctgtattg tgcccgggcc catggggagg acgatggtga ggagatcctg ttggacaccc 3060
 agtgccaggg gctgcctcgc ccggaacccc aggaggcctg cagcctggag ccctgcccac 3120
 ctagggtgaa agtcatgtcc cttggcccat gttcgccag ctgtggcctt ggcaactgcta 3180
 25 gacgctcgggt ggcctgtgtg cagctcgacc aaggccagga cgtggaggtg gacgaggcgg 3240
 cctgtgcggc gctggtgcgg ccgaggcca gtgtccctg tctcattgcc gactgcacct 3300
 accgctggca tgttgccacc tggatggagt gctctgtttc ctgtggggat ggcatccagc 3360
 gccggcgtga cacctgcctc ggaccccagg ccagggcgcc tgtgccagct gatttctgcc 3420
 agcaactgcc caagccggtg aotgtgcgtg gctgctgggc tgggccctgt gtgggacagg 3480
 30 gtaagcccag cctggtgccc cacgaagaag ccgctgctcc aggacggacc acagccaccc 3540
 ctgctggtgc ctccctggag tggctccagg ccggggcct gctcttctcc ccggctcccc 3600
 agcctcggcg gctcctgccc gggccccagg aaaactcagt gcagtccagt gcctgtggca 3660
 ggcagcacct tgagccaaca ggaaccattg acatgcgagg ccagggcag gcagactgtg 3720
 cagtggccat tgggcggccc ctcggggagg tggtagacct ccgctcctt gagagttctc 3780
 35 tcaactgcag tgccgggggac atgttgctgc tttggggccg gctcacctgg aggaagatgt 3840
 gcaggaagct gttggacatg actttcagct ccaagaccaa cacgctggtg gtgaggcagc 3900
 gctgcgggcg gccaggaggt ggggtgctgc tgcggtatgg gagccagctt gctcctgaaa 3960
 ccttctacag agaatgtgac atgcagctct ttgggccctg ggtgaaatc gtgagccct 4020
 cgctgagtcc agccacgagt aatgcagggg gctgccggct cttcattaat gtggtccgc 4080
 40 acgcacggat tgccatccat gccctggcca ccaacatggg cgctgggacc gagggagcca 4140
 atgccagcta catcttgatc cgggacaccc acagcttgag gaccacagcg ttccatgggc 4200
 agcagggtgct ctactgggag tcagagagca gccaggctga gatggagttc agcgagggt 4260
 tcctgaaggc tcaggccagc ctgcggggcc agtactggac cctccaatca tgggtaccgg 4320

```

agatgcagga ccctcagtc tggaagggaa aggaaggaac ctgaggggtca ttgaacattt 4380
gttcogtgto tggccagccc tggaggggttg acccctggto tcagtgccttt ccaattcgaa 4440
ctttttccaa tcttaggtat ctactttaga gtcttctcca atgtccaaaa ggctaggggg 4500
ttggaggtgg ggactctgga aaagcagccc ccatttcttc gggtaccaat aaataaaaca 4560
5   tgcaggcaaa aaaaaaaaaa aaaaaa 4585

<210> 7
<211> 4284
10  <212> DNA
    <213> Homo sapiens

<220>
<221> CDS
15  <222> (1)..(4284)

<400> 7
atg cac cag cgt cac ccc cgg gca aga tgc cct ccc ctc tgt gtg gcc 48
Met His Gln Arg His Pro Arg Ala Arg Cys Pro Pro Leu Cys Val Ala
20   1 5 10 15

gga atc ctt gcc tgt ggc ttt ctc ctg ggc tgc tgg gga ccc tcc cat 96
Gly Ile Leu Ala Cys Gly Phe Leu Leu Gly Cys Trp Gly Pro Ser His
25   20 25 30

ttc cag cag agt tgt ctt cag gct ttg gag cca cag gcc gtg tct tct 144
Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala Val Ser Ser
30   35 40 45

tac ttg agc cct ggt gct ccc tta aaa ggc cgc cct cct tcc cct ggc 192
Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro Pro Ser Pro Gly
35   50 55 60

ttc cag agg cag agg cag agg cag agg cgg gct gca ggc ggc atc cta 240
Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg Ala Ala Gly Gly Ile Leu
40   65 70 75 80

cac ctg gag ctg ctg gtg gcc gtg ggc ccc gat gtc ttc cag gct cac 288
His Leu Glu Leu Leu Val Ala Val Gly Pro Asp Val Phe Gln Ala His
45   85 90 95

cag gag gac aca gag cgc tat gtg ctc acc aac ctc aac atc ggg gca 336
Gln Glu Asp Thr Glu Arg Tyr Val Leu Thr Asn Leu Asn Ile Gly Ala
50   100 105 110

gaa ctg ctt cgg gac ccg tcc ctg ggg gct cag ttt cgg gtg cac ctg 384
Glu Leu Leu Arg Asp Pro Ser Leu Gly Ala Gln Phe Arg Val His Leu
55   115 120 125

gtg aag atg gtc att ctg aca gag cct gag ggt gct cca aat atc aca 432
Val Lys Met Val Ile Leu Thr Glu Pro Glu Gly Ala Pro Asn Ile Thr
60   130 135 140

```

		gcc aac ctc acc tcg tcc ctg ctg agc gtc tgt ggg tgg agc cag acc	480
		Ala Asn Leu Thr Ser Ser Leu Leu Ser Val Cys Gly Trp Ser Gln Thr	
		145 150 155 160	
5		atc aac cct gag gac gac acg gat cct ggc cat gct gac ctg gtc ctc	528
		Ile Asn Pro Glu Asp Asp Thr Asp Pro Gly His Ala Asp Leu Val Leu	
		165 170 175	
10		tat atc act agg ttt gac ctg gag ttg cct gat ggt aac cgg cag gtg	576
		Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro Asp Gly Asn Arg Gln Val	
		180 185 190	
15		cgg ggc gtc acc cag ctg ggc ggt gcc tgc tcc cca acc tgg agc tgc	624
		Arg Gly Val Thr Gln Leu Gly Gly Ala Cys Ser Pro Thr Trp Ser Cys	
		195 200 205	
20		ctc att acc gag gac act ggc ttc gac ctg gga gtc acc att gcc cat	672
		Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu Gly Val Thr Ile Ala His	
		210 215 220	
		gag att ggg cac agc ttc ggc ctg gag cac gac ggc gcg ccc ggc agc	720
		Glu Ile Gly His Ser Phe Gly Leu Glu His Asp Gly Ala Pro Gly Ser	
		225 230 235 240	
25		ggc tgc ggc ccc agc gga cac gtg atg gct tcg gac ggc gcc gcg ccc	768
		Gly Cys Gly Pro Ser Gly His Val Met Ala Ser Asp Gly Ala Ala Pro	
		245 250 255	
30		cgc gcc ggc ctc gcc tgg tcc ccc tgc agc cgc cgg cag ctg ctg agc	816
		Arg Ala Gly Leu Ala Trp Ser Pro Cys Ser Arg Arg Gln Leu Ser	
		260 265 270	
35		ctg ctc agc gca gga cgg gcg cgc tgc gtg tgg gac ccg ccg cgg cct	864
		Leu Leu Ser Ala Gly Arg Ala Arg Cys Val Trp Asp Pro Pro Arg Pro	
		275 280 285	
40		caa ccc ggg tcc gcg ggg cac ccg ccg gat gcg cag cct ggc ctc tac	912
		Gln Pro Gly Ser Ala Gly His Pro Pro Asp Ala Gln Pro Gly Leu Tyr	
		290 295 300	
		tac agc gcc aac gag cag tgc cgc gtg gcc ttc ggc ccc aag gct gtc	960
		Tyr Ser Ala Asn Glu Gln Cys Arg Val Ala Phe Gly Pro Lys Ala Val	
		305 310 315 320	
45		gcc tgc acc ttc gcc agg gag cac ctg gat atg tgc cag gcc ctc tcc	1008
		Ala Cys Thr Phe Ala Arg Glu His Leu Asp Met Cys Gln Ala Leu Ser	
		325 330 335	
50		tgc cac aca gac ccg ctg gac caa agc agc tgc agc cgc ctc ctc gtt	1056
		Cys His Thr Asp Pro Leu Asp Gln Ser Ser Cys Ser Arg Leu Leu Val	
		340 345 350	
55		cct ctc ctg gat ggg aca gaa tgt ggc gtg gag aag tgg tgc tcc aag	1104
		Pro Leu Leu Asp Gly Thr Glu Cys Gly Val Glu Lys Trp Cys Ser Lys	
		355 360 365	

	ggt cgc tgc cgc tcc ctg gtg gag ctg acc ccc ata gca gca gtg cat	1152
	Gly Arg Cys Arg Ser Leu Val Glu Leu Thr Pro Ile Ala Ala Val His	
	370 375 380	
5	ggg cgc tgg tct agc tgg ggt ccc cga agt cct tgc tcc cgc tcc tgc	1200
	Gly Arg Trp Ser Ser Trp Gly Pro Arg Ser Pro Cys Ser Arg Ser Cys	
	385 390 395 400	
10	gga gga ggt gtg gtc acc agg agg cgg cag tgc aac aac ccc aga cct	1248
	Gly Gly Gly Val Val Thr Arg Arg Arg Gln Cys Asn Asn Pro Arg Pro	
	405 410 415	
15	gcc ttt ggg ggg cgt gca tgt gtt ggt gct gac ctc cag gcc gag atg	1296
	Ala Phe Gly Gly Arg Ala Cys Val Gly Ala Asp Leu Gln Ala Glu Met	
	420 425 430	
20	tgc aac act cag gcc tgc gag aag acc cag ctg gag ttc atg tcg caa	1344
	Cys Asn Thr Gln Ala Cys Glu Lys Thr Gln Leu Glu Phe Met Ser Gln	
	435 440 445	
25	cag tgc gcc agg acc gac ggc cag ccg ctg cgc tcc tcc cct ggc ggc	1392
	Gln Cys Ala Arg Thr Asp Gly Gln Pro Leu Arg Ser Ser Pro Gly Gly	
	450 455 460	
30	gcc tcc ttc tac cac tgg ggt gct gct gta cca cac agc caa ggg gat	1440
	Ala Ser Phe Tyr His Trp Gly Ala Ala Val Pro His Ser Gln Gly Asp	
	465 470 475 480	
35	gct ctg tgc aga cac atg tgc cgg gcc att ggc gag agc ttc atc atg	1488
	Ala Leu Cys Arg His Met Cys Arg Ala Ile Gly Glu Ser Phe Ile Met	
	485 490 495	
40	aag cgt gga gac agc ttc ctc gat ggg acc cgg tgt atg cca agt ggc	1536
	Lys Arg Gly Asp Ser Phe Leu Asp Gly Thr Arg Cys Met Pro Ser Gly	
	500 505 510	
45	ccc cgg gag gac ggg acc ctg agc ctg tgt gtg tcg ggc agc tgc agg	1584
	Pro Arg Glu Asp Gly Thr Leu Ser Leu Cys Val Ser Gly Ser Cys Arg	
	515 520 525	
50	aca ttt ggc tgt gat ggt agg atg gac tcc cag cag gta tgg gac agg	1632
	Thr Phe Gly Cys Asp Gly Arg Met Asp Ser Gln Gln Val Trp Asp Arg	
	530 535 540	
55	tgc cag gtg tgt ggt ggg gac aac agc acg tgc agc cca cgg aag ggc	1680
	Cys Gln Val Cys Gly Gly Asp Asn Ser Thr Cys Ser Pro Arg Lys Gly	
	545 550 555 560	
55	tct ttc aca gct ggc aga gcg aga gaa tat gtc acg ttt ctg aca gtt	1728
	Ser Phe Thr Ala Gly Arg Ala Arg Glu Tyr Val Thr Phe Leu Thr Val	
	565 570 575	
55	acc ccc aac ctg acc agt gtc tac att gcc aac cac agg cct ctc ttc	1776
	Thr Pro Asn Leu Thr Ser Val Tyr Ile Ala Asn His Arg Pro Leu Phe	
	580 585 590	

	aca cac ttg gcg gtg agg atc gga ggg cgc tat gtc gtg gct ggg aag 1824
	Thr His Leu Ala Val Arg Ile Gly Gly Arg Tyr Val Val Ala Gly Lys
	595 600 605
5	atg agc atc tcc cct aac acc acc tac ccc tcc ctc ctg gag gat ggt 1872
	Met Ser Ile Ser Pro Asn Thr Thr Tyr Pro Ser Leu Leu Glu Asp Gly
	610 615 620
10	cgt gtc gag tac aga gtg gcc ctc acc gag gac cgg ctg ccc cgc ctg 1920
	Arg Val Glu Tyr Arg Val Ala Leu Thr Glu Asp Arg Leu Pro Arg Leu
	625 630 635 640
15	gag gag atc cgc atc tgg gga ccc ctc cag gaa gat gct gac atc cag 1968
	Glu Glu Ile Arg Ile Trp Gly Pro Leu Gln Glu Asp Ala Asp Ile Gln
	645 650 655
20	gtt tac agg cgg tat ggc gag gag tat ggc aac ctc acc cgc cca gac 2016
	Val Tyr Arg Arg Tyr Gly Glu Glu Tyr Gly Asn Leu Thr Arg Pro Asp
	660 665 670
	atc acc ttc acc tac ttc cag cct aag cca cgg cag gcc tgg gtg tgg 2064
	Ile Thr Phe Thr Tyr Phe Gln Pro Lys Pro Arg Gln Ala Trp Val Trp
	675 680 685
25	gcc gct gtg cgt ggg ccc tgc tgc gtg agc tgt ggg gca ggg ctg cgc 2112
	Ala Ala Val Arg Gly Pro Cys Ser Val Ser Cys Gly Ala Gly Leu Arg
	690 695 700
30	tgg gta aac tac agc tgc ctg gac cag gcc agg aag gag ttg gtg gag 2160
	Trp Val Asn Tyr Ser Cys Leu Asp Gln Ala Arg Lys Glu Leu Val Glu
	705 710 715 720
35	act gtc cag tgc caa ggg agc cag cag cca cca gcg tgg cca gag gcc 2208
	Thr Val Gln Cys Gln Gly Ser Gln Gln Pro Pro Ala Trp Pro Glu Ala
	725 730 735
40	tgc gtg ctc gaa ccc tgc cct ccc tac tgg gcg gtg gga gac ttc ggc 2256
	Cys Val Leu Glu Pro Cys Pro Pro Tyr Trp Ala Val Gly Asp Phe Gly
	740 745 750
	cca tgc agc gcc tcc tgt ggg ggt ggc ctg cgg gag cgg cca gtg cgc 2304
	Pro Cys Ser Ala Ser Cys Gly Gly Gly Leu Arg Glu Arg Pro Val Arg
	755 760 765
45	tgc gtg gag gcc cag ggc agc ctc ctg aag aca ttg ccc cca gcc cgg 2352
	Cys Val Glu Ala Gln Gly Ser Leu Leu Lys Thr Leu Pro Pro Ala Arg
	770 775 780
50	tgc aga gca ggg gcc cag cag cca gct gtg gcg ctg gaa acc tgc aac 2400
	Cys Arg Ala Gly Ala Gln Gln Pro Ala Val Ala Leu Glu Thr Cys Asn
	785 790 795 800
55	ccc cag ccc tgc cct gcc agg tgg gag gtg tca gag ccc agc tca tgc 2448
	Pro Gln Pro Cys Pro Ala Arg Trp Glu Val Ser Glu Pro Ser Ser Cys
	805 810 815

	aca tca gct ggt gga gca ggc ctg gcc ttg gag aac gag acc tgt gtg	2496
	Thr Ser Ala Gly Gly Ala Gly Leu Ala Leu Glu Asn Glu Thr Cys Val	
	820 825 830	
5	cca ggg gca gat ggc ctg gag gct cca gtg act gag ggg cct ggc tcc	2544
	Pro Gly Ala Asp Gly Leu Glu Ala Pro Val Thr Glu Gly Pro Gly Ser	
	835 840 845	
10	gta gat gag aag ctg cct gcc cct gag ccc tgt gtc ggg atg tca tgt	2592
	Val Asp Glu Lys Leu Pro Ala Pro Glu Pro Cys Val Gly Met Ser Cys	
	850 855 860	
15	cct cca ggc tgg ggc cat ctg gat gcc acc tct gca ggg gag aag gct	2640
	Pro Pro Gly Trp Gly His Leu Asp Ala Thr Ser Ala Gly Glu Lys Ala	
	865 870 875 880	
20	ccc tcc cca tgg ggc agc atc agg acg ggg gct caa gct gca cac gtg	2688
	Pro Ser Pro Trp Gly Ser Ile Arg Thr Gly Ala Gln Ala Ala His Val	
	885 890 895	
	tgg acc cct gcg gca ggg tgg tgc tcc gtc tcc tgc ggg cga ggt ctg	2736
	Trp Thr Pro Ala Ala Gly Ser Cys Ser Val Ser Cys Gly Arg Gly Leu	
	900 905 910	
25	atg gag ctg cgt ttc ctg tgc atg gac tct gcc ctc agg gtg cct gtc	2784
	Met Glu Leu Arg Phe Leu Cys Met Asp Ser Ala Leu Arg Val Pro Val	
	915 920 925	
30	cag gaa gag ctg tgt ggc ctg gca agc aag cct ggg agc cgg cgg gag	2832
	Gln Glu Glu Leu Cys Gly Leu Ala Ser Lys Pro Gly Ser Arg Arg Glu	
	930 935 940	
35	gtc tgc cag gct gtc ccg tgc cct gct cgg tgg cag tac aag ctg gcg	2880
	Val Cys Gln Ala Val Pro Cys Pro Ala Arg Trp Gln Tyr Lys Leu Ala	
	945 950 955 960	
40	gcc tgc agc gtg agc tgt ggg aga ggg gtc gtg cgg agg atc ctg tat	2928
	Ala Cys Ser Val Ser Cys Gly Arg Gly Val Val Arg Arg Ile Leu Tyr	
	965 970 975	
	tgt gcc cgg gcc cat ggg gag gac gat ggt gag gag atc ctg ttg gac	2976
	Cys Ala Arg Ala His Gly Glu Asp Asp Gly Glu Glu Ile Leu Leu Asp	
	980 985 990	
45	acc cag tgc cag ggg ctg cct cgc ccg gaa ccc cag gag gcc tgc agc	3024
	Thr Gln Cys Gln Gly Leu Pro Arg Pro Glu Pro Gln Glu Ala Cys Ser	
	995 1000 1005	
50	ctg gag ccc tgc cca cct agg tgg aaa gtc atg tcc ctt ggc cca tgt	3072
	Leu Glu Pro Cys Pro Pro Arg Trp Lys Val Met Ser Leu Gly Pro Cys	
	1010 1015 1020	
55	tcg gcc agc tgt ggc ctt ggc act gct aga cgc tcg gtg gcc tgt gtg	3120
	Ser Ala Ser Cys Gly Leu Gly Thr Ala Arg Ser Val Ala Cys Val	
	1025 1030 1035 1040	

	cag ctc gac caa ggc cag gac gtg gag gtg gac gag gcg gcc tgt gcg	3168
	Gln Leu Asp Gln Gly Gln Asp Val Glu Val Asp Glu Ala Ala Cys Ala	
	1045 1050 1055	
5	gcg ctg gtg cgg ccc gag gcc agt gtc ccc tgt ctc att gcc gac tgc	3216
	Ala Leu Val Arg Pro Glu Ala Ser Val Pro Cys Leu Ile Ala Asp Cys	
	1060 1065 1070	
10	acc tac cgc tgg cat gtt ggc acc tgg atg gag tgc tct gtt tcc tgt	3264
	Thr Tyr Arg Trp His Val Gly Thr Trp Met Glu Cys Ser Val Ser Cys	
	1075 1080 1085	
15	ggg gat ggc atc cag cgc cgg cgt gac acc tgc ctc gga ccc cag gcc	3312
	Gly Asp Gly Ile Gln Arg Arg Arg Asp Thr Cys Leu Gly Pro Gln Ala	
	1090 1095 1100	
20	cag gcg cct gtg cca gct gat ttc tgc cag cac ttg ccc aag ccg gtg	3360
	Gln Ala Pro Val Pro Ala Asp Phe Cys Gln His Leu Pro Lys Pro Val	
	1105 1110 1115 1120	
	act gtg cgt ggc tgc tgg gct ggg ccc tgt gtg gga cag ggt acg ccc	3408
	Thr Val Arg Gly Cys Trp Ala Gly Pro Cys Val Gly Gln Gly Thr Pro	
	1125 1130 1135	
25	agc ctg gtg ccc cac gaa gaa gcc gct gct cca gga cgg acc aca gcc	3456
	Ser Leu Val Pro His Glu Glu Ala Ala Ala Pro Gly Arg Thr Thr Ala	
	1140 1145 1150	
30	acc cct gct ggt gcc tcc ctg gag tgg tcc cag gcc cgg ggc ctg ctc	3504
	Thr Pro Ala Gly Ala Ser Leu Glu Trp Ser Gln Ala Arg Gly Leu Leu	
	1155 1160 1165	
35	ttc tcc ccg gct ccc cag cct cgg cgg ctc ctg ccc ggg ccc cag gaa	3552
	Phe Ser Pro Ala Pro Gln Pro Arg Arg Leu Leu Pro Gly Pro Gln Glu	
	1170 1175 1180	
40	aac tca gtg cag tcc agt gcc tgt ggc agg cag cac ctt gag cca aca	3600
	Asn Ser Val Gln Ser Ser Ala Cys Gly Arg Gln His Leu Glu Pro Thr	
	1185 1190 1195 1200	
	gga acc att gac atg cga ggc cca ggg cag gca gac tgt gca gtg gcc	3648
	Gly Thr Ile Asp Met Arg Gly Pro Gly Gln Ala Asp Cys Ala Val Ala	
	1205 1210 1215	
45	att ggg cgg ccc ctc ggg gag gtg gtg acc ctc cgc gtc ctt gag agt	3696
	Ile Gly Arg Pro Leu Gly Glu Val Val Thr Leu Arg Val Leu Glu Ser	
	1220 1225 1230	
50	tct ctc aac tgc agt gcg ggg gac atg ttg ctg ctt tgg ggc cgg ctc	3744
	Ser Leu Asn Cys Ser Ala Gly Asp Met Leu Leu Leu Trp Gly Arg Leu	
	1235 1240 1245	
55	acc tgg agg aag atg tgc agg aag ctg ttg gac atg act ttc agc tcc	3792
	Thr Trp Arg Lys Met Cys Arg Lys Leu Leu Asp Met Thr Phe Ser Ser	
	1250 1255 1260	

aag acc aac acg ctg gtg gtg agg cag cgc tgc ggg cgg cca gga ggt 3840
 Lys Thr Asn Thr Leu Val Val Arg Gln Arg Cys Gly Arg Pro Gly Gly
 1265 1270 1275 1280

5 ggg gtg ctg ctg cgg tat ggg agc cag ctt gct cct gaa acc ttc tac 3888
 Gly Val Leu Leu Arg Tyr Gly Ser Gln Leu Ala Pro Glu Thr Phe Tyr
 1285 1290 1295

10 aga gaa tgt gac atg cag ctc ttt ggg ccc tgg ggt gaa atc gtg agc 3936
 Arg Glu Cys Asp Met Gln Leu Phe Gly Pro Trp Gly Glu Ile Val Ser
 1300 1305 1310

15 ccc tcg ctg agt cca gcc acg agt aat gca ggg ggc tgc cgg ctc ttc 3984
 Pro Ser Leu Ser Pro Ala Thr Ser Asn Ala Gly Gly Cys Arg Leu Phe
 1315 1320 1325

20 att aat gtg gct ccg cac gca cgg att gcc atc cat gcc ctg gcc acc 4032
 Ile Asn Val Ala Pro His Ala Arg Ile Ala Ile His Ala Leu Ala Thr
 1330 1335 1340

aac atg ggc gct ggg acc gag gga gcc aat gcc agc tac atc ttg atc 4080
 Asn Met Gly Ala Gly Thr Glu Gly Ala Asn Ala Ser Tyr Ile Leu Ile
 1345 1350 1355 1360

25 cgg gac acc cac agc ttg agg acc aca gcg ttc cat ggg cag cag gtg 4128
 Arg Asp Thr His Ser Leu Arg Thr Thr Ala Phe His Gly Gln Gln Val
 1365 1370 1375

30 ctc tac tgg gag tca gag agc agc cag gct gag atg gag ttc agc gag 4176
 Leu Tyr Trp Glu Ser Glu Ser Ser Gln Ala Glu Met Glu Phe Ser Glu
 1380 1385 1390

35 ggc ttc ctg aag gct cag gcc agc ctg cgg ggc cag tac tgg acc ctc 4224
 Gly Phe Leu Lys Ala Gln Ala Ser Leu Arg Gly Gln Tyr Trp Thr Leu
 1395 1400 1405

40 caa tca tgg gta ccg gag atg cag gac cct cag tcc tgg aag gga aag 4272
 Gln Ser Trp Val Pro Glu Met Gln Asp Pro Gln Ser Trp Lys Gly Lys
 1410 1415 1420

gaa gga acc tga 4284
 Glu Gly Thr
 1425

45 <210> 8
 <211> 1427
 <212> PRT
 <213> Homo sapiens

50 <400> 8
 Met His Gln Arg His Pro Arg Ala Arg Cys Pro Pro Leu Cys Val Ala
 1 5 10 15

55 Gly Ile Leu Ala Cys Gly Phe Leu Leu Gly Cys Trp Gly Pro Ser His
 20 25 30

Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala Val Ser Ser
 35 40 45
 5 Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro Pro Ser Pro Gly
 50 55 60
 Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg Ala Ala Gly Gly Ile Leu
 65 70 75 80
 10 His Leu Glu Leu Leu Val Ala Val Gly Pro Asp Val Phe Gln Ala His
 85 90 95
 Gln Glu Asp Thr Glu Arg Tyr Val Leu Thr Asn Leu Asn Ile Gly Ala
 100 105 110
 15 Glu Leu Leu Arg Asp Pro Ser Leu Gly Ala Gln Phe Arg Val His Leu
 115 120 125
 20 Val Lys Met Val Ile Leu Thr Glu Pro Glu Gly Ala Pro Asn Ile Thr
 130 135 140
 Ala Asn Leu Thr Ser Ser Leu Leu Ser Val Cys Gly Trp Ser Gln Thr
 145 150 155 160
 25 Ile Asn Pro Glu Asp Asp Thr Asp Pro Gly His Ala Asp Leu Val Leu
 165 170 175
 Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro Asp Gly Asn Arg Gln Val
 180 185 190
 30 Arg Gly Val Thr Gln Leu Gly Gly Ala Cys Ser Pro Thr Trp Ser Cys
 195 200 205
 35 Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu Gly Val Thr Ile Ala His
 210 215 220
 Glu Ile Gly His Ser Phe Gly Leu Glu His Asp Gly Ala Pro Gly Ser
 225 230 235 240
 40 Gly Cys Gly Pro Ser Gly His Val Met Ala Ser Asp Gly Ala Ala Pro
 245 250 255
 Arg Ala Gly Leu Ala Trp Ser Pro Cys Ser Arg Arg Gln Leu Leu Ser
 260 265 270
 45 Leu Leu Ser Ala Gly Arg Ala Arg Cys Val Trp Asp Pro Pro Arg Pro
 275 280 285
 50 Gln Pro Gly Ser Ala Gly His Pro Pro Asp Ala Gln Pro Gly Leu Tyr
 290 295 300
 Tyr Ser Ala Asn Glu Gln Cys Arg Val Ala Phe Gly Pro Lys Ala Val
 305 310 315 320
 55 Ala Cys Thr Phe Ala Arg Glu His Leu Asp Met Cys Gln Ala Leu Ser
 325 330 335

	Cys His Thr Asp Pro Leu Asp Gln Ser Ser Cys Ser Arg Leu Leu Val	
	340	345 350
5	Pro Leu Leu Asp Gly Thr Glu Cys Gly Val Glu Lys Trp Cys Ser Lys	
	355	360 365
10	Gly Arg Cys Arg Ser Leu Val Glu Leu Thr Pro Ile Ala Ala Val His	
	370	375 380
	Gly Arg Trp Ser Ser Trp Gly Pro Arg Ser Pro Cys Ser Arg Ser Cys	
	385	390 395 400
15	Gly Gly Gly Val Val Thr Arg Arg Arg Gln Cys Asn Asn Pro Arg Pro	
	405	410 415
	Ala Phe Gly Gly Arg Ala Cys Val Gly Ala Asp Leu Gln Ala Glu Met	
	420	425 430
20	Cys Asn Thr Gln Ala Cys Glu Lys Thr Gln Leu Glu Phe Met Ser Gln	
	435	440 445
	Gln Cys Ala Arg Thr Asp Gly Gln Pro Leu Arg Ser Ser Pro Gly Gly	
	450	455 460
25	Ala Ser Phe Tyr His Trp Gly Ala Ala Val Pro His Ser Gln Gly Asp	
	465	470 475 480
30	Ala Leu Cys Arg His Met Cys Arg Ala Ile Gly Glu Ser Phe Ile Met	
	485	490 495
	Lys Arg Gly Asp Ser Phe Leu Asp Gly Thr Arg Cys Met Pro Ser Gly	
	500	505 510
35	Pro Arg Glu Asp Gly Thr Leu Ser Leu Cys Val Ser Gly Ser Cys Arg	
	515	520 525
	Thr Phe Gly Cys Asp Gly Arg Met Asp Ser Gln Gln Val Trp Asp Arg	
	530	535 540
40	Cys Gln Val Cys Gly Gly Asp Asn Ser Thr Cys Ser Pro Arg Lys Gly	
	545	550 555 560
45	Ser Phe Thr Ala Gly Arg Ala Arg Glu Tyr Val Thr Phe Leu Thr Val	
	565	570 575
	Thr Pro Asn Leu Thr Ser Val Tyr Ile Ala Asn His Arg Pro Leu Phe	
	580	585 590
50	Thr His Leu Ala Val Arg Ile Gly Gly Arg Tyr Val Val Ala Gly Lys	
	595	600 605
55	Met Ser Ile Ser Pro Asn Thr Thr Tyr Pro Ser Leu Leu Glu Asp Gly	
	610	615 620

	Arg Val Glu Tyr Arg Val Ala Leu Thr Glu Asp Arg Leu Pro Arg Leu	625	630	635	640
5	Glu Glu Ile Arg Ile Trp Gly Pro Leu Gln Glu Asp Ala Asp Ile Gln		645	650	655
	Val Tyr Arg Arg Tyr Gly Glu Glu Tyr Gly Asn Leu Thr Arg Pro Asp		660	665	670
10	Ile Thr Phe Thr Tyr Phe Gln Pro Lys Pro Arg Gln Ala Trp Val Trp		675	680	685
	Ala Ala Val Arg Gly Pro Cys Ser Val Ser Cys Gly Ala Gly Leu Arg		690	695	700
15	Trp Val Asn Tyr Ser Cys Leu Asp Gln Ala Arg Lys Glu Leu Val Glu		705	710	715
	Thr Val Gln Cys Gln Gly Ser Gln Gln Pro Pro Ala Trp Pro Glu Ala		725	730	735
20	Cys Val Leu Glu Pro Cys Pro Pro Tyr Trp Ala Val Gly Asp Phe Gly		740	745	750
	Pro Cys Ser Ala Ser Cys Gly Gly Gly Leu Arg Glu Arg Pro Val Arg		755	760	765
	Cys Val Glu Ala Gln Gly Ser Leu Leu Lys Thr Leu Pro Pro Ala Arg		770	775	780
30	Cys Arg Ala Gly Ala Gln Gln Pro Ala Val Ala Leu Glu Thr Cys Asn		785	790	795
	Pro Gln Pro Cys Pro Ala Arg Trp Glu Val Ser Glu Pro Ser Ser Cys		805	810	815
	Thr Ser Ala Gly Gly Ala Gly Leu Ala Leu Glu Asn Glu Thr Cys Val		820	825	830
40	Pro Gly Ala Asp Gly Leu Glu Ala Pro Val Thr Glu Gly Pro Gly Ser		835	840	845
	Val Asp Glu Lys Leu Pro Ala Pro Glu Pro Cys Val Gly Met Ser Cys		850	855	860
45	Pro Pro Gly Trp Gly His Leu Asp Ala Thr Ser Ala Gly Glu Lys Ala		865	870	875
	Pro Ser Pro Trp Gly Ser Ile Arg Thr Gly Ala Gln Ala Ala His Val		885	890	895
	Trp Thr Pro Ala Ala Gly Ser Cys Ser Val Ser Cys Gly Arg Gly Leu		900	905	910
55	Met Glu Leu Arg Phe Leu Cys Met Asp Ser Ala Leu Arg Val Pro Val		915	920	925

	Gln	Glu	Glu	Leu	Cys	Gly	Leu	Ala	Ser	Lys	Pro	Gly	Ser	Arg	Arg	Glu	
	930						935					940					
5	Val	Cys	Gln	Ala	Val	Pro	Cys	Pro	Ala	Arg	Trp	Gln	Tyr	Lys	Leu	Ala	
	945					950					955					960	
	Ala	Cys	Ser	Val	Ser	Cys	Gly	Arg	Gly	Val	Val	Arg	Arg	Ile	Leu	Tyr	
					965					970					975		
10	Cys	Ala	Arg	Ala	His	Gly	Glu	Asp	Asp	Gly	Glu	Glu	Ile	Leu	Leu	Asp	
				980					985					990			
	Thr	Gln	Cys	Gln	Gly	Leu	Pro	Arg	Pro	Glu	Pro	Gln	Glu	Ala	Cys	Ser	
			995					1000					1005				
15	Leu	Glu	Pro	Cys	Pro	Pro	Arg	Trp	Lys	Val	Met	Ser	Leu	Gly	Pro	Cys	
	1010						1015					1020					
20	Ser	Ala	Ser	Cys	Gly	Leu	Gly	Thr	Ala	Arg	Arg	Ser	Val	Ala	Cys	Val	
	1025					1030				1035						1040	
	Gln	Leu	Asp	Gln	Gly	Gln	Asp	Val	Glu	Val	Asp	Glu	Ala	Ala	Cys	Ala	
				1045					1050					1055			
25	Ala	Leu	Val	Arg	Pro	Glu	Ala	Ser	Val	Pro	Cys	Leu	Ile	Ala	Asp	Cys	
			1060						1065				1070				
	Thr	Tyr	Arg	Trp	His	Val	Gly	Thr	Trp	Met	Glu	Cys	Ser	Val	Ser	Cys	
		1075					1080					1085					
30	Gly	Asp	Gly	Ile	Gln	Arg	Arg	Arg	Asp	Thr	Cys	Leu	Gly	Pro	Gln	Ala	
	1090					1095						1100					
	Gln	Ala	Pro	Val	Pro	Ala	Asp	Phe	Cys	Gln	His	Leu	Pro	Lys	Pro	Val	
35	1105				1110					1115					1120		
	Thr	Val	Arg	Gly	Cys	Trp	Ala	Gly	Pro	Cys	Val	Gly	Gln	Gly	Thr	Pro	
				1125					1130					1135			
40	Ser	Leu	Val	Pro	His	Glu	Glu	Ala	Ala	Ala	Pro	Gly	Arg	Thr	Thr	Ala	
			1140					1145					1150				
	Thr	Pro	Ala	Gly	Ala	Ser	Leu	Glu	Trp	Ser	Gln	Ala	Arg	Gly	Leu	Leu	
		1155					1160					1165					
45	Phe	Ser	Pro	Ala	Pro	Gln	Pro	Arg	Arg	Leu	Leu	Pro	Gly	Pro	Gln	Glu	
	1170					1175						1180					
	Asn	Ser	Val	Gln	Ser	Ser	Ala	Cys	Gly	Arg	Gln	His	Leu	Glu	Pro	Thr	
50	1185				1190					1195					1200		
	Gly	Thr	Ile	Asp	Met	Arg	Gly	Pro	Gly	Gln	Ala	Asp	Cys	Ala	Val	Ala	
				1205					1210				1215				
55	Ile	Gly	Arg	Pro	Leu	Gly	Glu	Val	Val	Thr	Leu	Arg	Val	Leu	Glu	Ser	
				1220				1225					1230				

Ser Leu Asn Cys Ser Ala Gly Asp Met Leu Leu Leu Trp Gly Arg Leu
 1235 1240 1245
 5 Thr Trp Arg Lys Met Cys Arg Lys Leu Leu Asp Met Thr Phe Ser Ser
 1250 1255 1260
 Lys Thr Asn Thr Leu Val Val Arg Gln Arg Cys Gly Arg Pro Gly Gly
 1265 1270 1275 1280
 10 Gly Val Leu Leu Arg Tyr Gly Ser Gln Leu Ala Pro Glu Thr Phe Tyr
 1285 1290 1295
 Arg Glu Cys Asp Met Gln Leu Phe Gly Pro Trp Gly Glu Ile Val Ser
 1300 1305 1310
 15 Pro Ser Leu Ser Pro Ala Thr Ser Asn Ala Gly Gly Cys Arg Leu Phe
 1315 1320 1325
 Ile Asn Val Ala Pro His Ala Arg Ile Ala Ile His Ala Leu Ala Thr
 1330 1335 1340
 Asn Met Gly Ala Gly Thr Glu Gly Ala Asn Ala Ser Tyr Ile Leu Ile
 1345 1350 1355 1360
 25 Arg Asp Thr His Ser Leu Arg Thr Thr Ala Phe His Gly Gln Gln Val
 1365 1370 1375
 Leu Tyr Trp Glu Ser Glu Ser Ser Gln Ala Glu Met Glu Phe Ser Glu
 1380 1385 1390
 30 Gly Phe Leu Lys Ala Gln Ala Ser Leu Arg Gly Gln Tyr Trp Thr Leu
 1395 1400 1405
 Gln Ser Trp Val Pro Glu Met Gln Asp Pro Gln Ser Trp Lys Gly Lys
 1410 1415 1420
 Glu Gly Thr
 1425
 40
 <210> 9
 <211> 45
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <222> (1)..(45)
 50
 <400> 9
 gctgcaggcg gcacccctaca cctggagctg ctggtggccg tgggc 45
 55 <210> 10
 <211> 20
 <212> DNA

<213> Artificial Sequence

<220>
<221> primer_bind
5 <222> (1)..(20)

<400> 10
cggcggggtac ctacacctgg 20

10 <210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

15 <220>
<221> primer_bind
<222> (1)..(20)

20 <400> 11
aatggtgact cccaggtcga 20

25 <210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

30 <220>
<221> primer_bind
<222> (1)..(20)

35 <400> 12
gagcaaattc ctgtactgac 20

40 <210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

45 <220>
<221> primer_bind
<222> (1)..(20)

<400> 13
gagcaaattc ctgtactgac 20

50 <210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

55 <220>
<221> primer_bind

<222> (1)..(22)
 <400> 14
 5 gaccacgcgt atcgacgtcg ac 22
 <210> 15
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <222> (1)..(21)
 15 <400> 15
 ctcagggttg atggtctggc t 21
 <210> 16
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <221> primer_bind
 <222> (1)..(30)
 <400> 16
 30 cgggctgcag gcgggatcct acacctggag 30
 <210> 17
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 40 <222> (1)..(21)
 <400> 17
 aatggtgact cccaggtcga g 21
 <210> 18
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <221> primer_bind
 <222> (1)..(20)
 <400> 18
 55 tggaggtcag caccaacaca 20

5 <210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

10 <220>
<221> primer_bind
<222> (1)..(20)

<400> 19
gagttgcctg atggtaacog 20

15 <210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

20 <220>
<221> primer_bind
<222> (1)..(20)

25 <400> 20
gagcccttcc gtgggctgca 20

30 <210> 21
<211> 21
<212> DNA
<213> Artificial Sequence

35 <220>
<221> primer_bind
<222> (1)..(21)

<400> 21
cgctccctgg tggagctgac c 21

40 <210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

45 <220>
<221> primer_bind
<222> (1)..(20)

50 <400> 22
ctcaccatcg tcctcccat 20

55 <210> 23
<211> 21
<212> DNA
<213> Artificial Sequence

	<220>		
	<221> primer_bind		
	<222> (1)..(21)		
5	<400> 23		
	atcatgaagc gtggagacag c		21
10	<210> 24		
	<211> 20		
	<212> DNA		
	<213> Artificial Sequence		
15	<220>		
	<221> primer_bind		
	<222> (1)..(20)		
	<400> 24		
20	cctggagggg tccccagatg		20
	<210> 25		
	<211> 20		
25	<212> DNA		
	<213> Artificial Sequence		
	<220>		
	<221> primer_bind		
30	<222> (1)..(20)		
	<400> 25		
	tcgagccac ggaagggtc		20
35	<210> 26		
	<211> 20		
	<212> DNA		
	<213> Artificial Sequence		
40	<220>		
	<221> primer_bind		
	<222> (1)..(20)		
45	<400> 26		
	cagggtcca ggctgcaggc		20
50	<210> 27		
	<211> 20		
	<212> DNA		
	<213> Artificial Sequence		
	<220>		
55	<221> primer_bind		
	<222> (1)..(20)		

<400> 27
 aggaagagct gtgtggcctg 20

5 <210> 28
 <211> 39
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <221> primer_bind
 <222> (1)..(39)

15 <400> 28
 gacgcggccc agccggccgc tgcaggcggc atcctacac 39

20 <210> 29
 <211> 34
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <221> primer_bind
 <222> (1)..(34)

<400> 29
 ggccctcgag cggttccttc ctttccttc cagg 34

30 <210> 30
 <211> 35
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <221> primer_bind
 <222> (1)..(35)

40 <400> 30
 agcgtctct atggctgcag gcggcatcct acacc 35

45 <210> 31
 <211> 30
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <221> primer_bind
 <222> (1)..(30)

55 <400> 31
 agcctcgagc tggccagaca cggaacaaat 30

	<210> 32	
	<211> 29	
	<212> DNA	
	<213> Artificial Sequence	
5	<220>	
	<221> primer_bind	
	<222> (1)..(29)	
10	<400> 32	
	ggcgaattca tgcaccagcg tcacccccg	29
	<210> 33	
15	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
20	<221> primer_bind	
	<222> (1)..(21)	
	<400> 33	
	acagcattaa actaagccgc c	21
25	<210> 34	
	<211> 40	
	<212> DNA	
30	<213> Artificial Sequence	
	<220>	
	<221> primer_bind	
	<222> (1)..(40)	
35	<400> 34	
	gatcgaattc gccggccacc atgcaccagc gtcacccccg	40
40	<210> 35	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
45	<220>	
	<221> primer_bind	
	<222> (1)..(21)	
	<400> 35	
50	cggataacaa tttcacacag g	21